University of Nebraska Medical Center

DigitalCommons@UNMC
Theses & Dissertations

Graduate Studies

Spring 5-5-2018

MUC4 Based Immunotherapy for Pancreatic Cancer
Kasturi Banerjee
University of Nebraska Medical Center

Follow this and additional works at: https://digitalcommons.unmc.edu/etd
Part of the Biological Phenomena, Cell Phenomena, and Immunity Commons, Biology Commons,
Disease Modeling Commons, Medical Cell Biology Commons, Medical Immunology Commons, Molecular
Biology Commons, Nanomedicine Commons, and the Translational Medical Research Commons

Recommended Citation
Banerjee, Kasturi, "MUC4 Based Immunotherapy for Pancreatic Cancer" (2018). Theses & Dissertations.
283.
https://digitalcommons.unmc.edu/etd/283

This Dissertation is brought to you for free and open access by the Graduate Studies at DigitalCommons@UNMC. It
has been accepted for inclusion in Theses & Dissertations by an authorized administrator of
DigitalCommons@UNMC. For more information, please contact digitalcommons@unmc.edu.

i

MUC4 BASED IMMUNOTHERAPY FOR
PANCREATIC CANCER
By

KASTURI BANERJEE
A DISSERTATION
Presented to the Faculty of
The University of Nebraska Graduate College
In Partial Fulfillment of the Requirements
For the Degree of Doctor of Philosophy

Biochemistry and Molecular Biology
Graduate Program

Under the Supervision of Associate Professor Dr. Maneesh Jain
University of Nebraska Medical Center
Omaha, Nebraska
April 2018
Supervisory Committee:
Surinder K. Batra, Ph.D.

Rakesh Singh, Ph.D.

Kaustubh Datta, Ph.D.

Joyce Solheim, Ph.D.

ii

DEDICATION
I dedicate my PhD dissertation to my father Mr. Chandan Banerjee, my mother
Mrs. Sarbasree Banerjee, my younger sister Ms. Sanchari Banerjee
And my late grandmother Mrs. Kalyani Banerjee
For providing me constant love and support.

iii

ACKNOWLEDGEMENTS
Firstly, I would like to express my sincere gratitude to my PI Maneesh Jain (PhD)
for the continuous support of my PhD study and related research, for his patience,
motivation, and immense knowledge. His faith in me to work on a cancer immunotherapy
project that is out of the norm of our lab had provided me with confidence to understand
research on a deeper level.

Besides my advisor, I would like to thank the rest of my thesis committee: Dr.
Surinder K. Batra, Dr. Joyce Solheim, Dr. Rakesh Singh and Dr. Kaustubh Datta, for their
insightful comments and encouragement, but also for the hard questions which incented
me to widen my research from various perspectives.

My sincere thanks also go to Dr. Shailendra Gautam, Dr. Prakash Kshirsagar, and
Dr. Mohd Wasim Nasser, for their precious support, without which it would not be possible
to conduct this research. I want to sincerely thank Dr. Sushil Kumar for mentoring me
through the MUC4 nanovaccine project, and Dr. Sukhwinder Kaur for guiding me in the
MUC4 autoantibody project. I will take this opportunity to thank our collaborator at Iowa
State University: Dr. Balaji Narasimhan, Dr. Kathleen Ross and Dr. Michael
Wannemuehler, for synthesizing and providing us with the nanoparticles and being very
responsive to my queries and emails.

I thank my fellow lab mates and friends: Saswati, Koelina, Rahat, Pranita and
Sanchita; for the stimulating discussions, for the sleepless nights we were working
together before deadlines, and for all the fun we have had in the last four and a half years.

iv
I want to thank my Alma Mater, IISER Mohali and all the faculties there who taught me
and developed my eagerness in scientific research.

I want to especially thank my school friend Abhishek Banerjee, who forced me to
apply for KVPY fellowship and that entirely changed my professional life and I will be
forever grateful to him for being an awesome friend. I owe to my friends Dr. Matharishwan
Naganbabu and Neelam Singh for constantly being my support during my PhD application
days and still valuing the meaning of friendship even when we live miles apart. I want to
thank Justin Garrison and Dr. Matthew Ingersoll for being valuable friend and support
throughout the initial stages of my PhD journey. I am grateful to all of you for having faith
in me and encouraging me to pursue my career in research.

A special thanks to Linda Bernadt for adopting me into her life as a granddaughter
and taking care of me emotionally, especially after I lost my late grandmother Mrs. Kalyani
Banerjee. I will forever be grateful to you for showering me with unconditional love and
support and making Omaha feel like home, away from my home in India. Last but never
the least, I would like to thank my family: my parents and my sister for supporting me
spiritually throughout writing this thesis and my life in general.

v

ABSTRACT
MUC4 based immunotherapy for pancreatic cancer
Kasturi Banerjee, Ph.D.
University of Nebraska Medical Center, 2018
Supervisor: Maneesh Jain, PhD.
Pancreatic Cancer (PC) is a lethal disease claiming approximately 45000 lives in
the US in 2018, and it establishes an elaborate immunosuppressive tumor
microenvironment that aids in disease pathogenesis. Immunotherapy has emerged as a
strategy to target tumor cells by reprogramming patient’s immune system. Challenges
present in PC immunotherapy are: i) identifying a tumor-associated antigen that could be
targeted, ii) identifying adjuvants that could efficiently deliver antigens, iii) eliciting robust
anti-tumor responses and iv) overcoming peripheral tolerance and immunosuppression
elicited by the tumor.
Firstly, we detected circulating autoantibodies to MUC4 present in PC patients and
observed that IgM autoantibodies to MUC4 peptides significantly correlate with overall PC
patient survival, thus suggesting that MUC4 could potentially be targeted for PC
immunotherapy. Our group is the first to successfully purify recombinant MUC4β protein
and characterize its immunogenic activity. We addressed the challenge of protein delivery
by encapsulating MUC4β in novel polyanhydride nanoparticles (MUC4 nanovaccine). In
the second part of the dissertation, we characterized MUC4 nanovaccine in both in vitro
and in vivo system. Our studies showed that MUC4 nanovaccine could robustly activate
dendritic cells (DCs) and induce secretion of Th1 cytokines in vitro. High levels of Th1
IgG2b anti-MUC4β antibodies were detected in MUC4 nanovaccine-immunized mice.
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As described in the third part of the dissertation, we observed that ex vivo T-cells
activated by MUC4 nanovaccine-pulsed DCs showed enhanced cytotoxic killing of
miniMUC4 tumor cells, when compared to soluble MUC4β mixed with empty nanoparticles
(MUC4+NP). We validated our data in an in vivo subcutaneous PC tumor mouse model,
and observed enhanced immune cells infiltration and corresponding levels of necrosis in
miniMUC4 tumors corroborated with low tumor volume of miniMUC4 tumor (in comparison
to contralateral vector control tumor) in MUC4-immunized mice. Furthermore, the
presence of PD-L1 surface expression on miniMUC4 tumor cells indicated active
immunosuppression lodged by tumor cells in response to IFNγ-secreting infiltrating
cytotoxic T-cells.
Taken together, studies in this dissertation demonstrate that MUC4 nanovaccine
could serve as a potential strategy for PC immunotherapy.
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CHAPTER 1A: INTRODUCTION
The material covered in this chapter is the subject of one review article

1. Banerjee K., Kumar S., Ross K. A., Gautam S., Poelaert B., Nasser M. W., Aithal A.,
Bhatia R., Wannemuehler M.J., Narasimhan B., Solheim J. C., Batra S. K. and Jain
M., Emerging trends in the immunotherapy of pancreatic cancer; Cancer Letters, 417
(2018) 35-46
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1. Synopsis
Pancreatic cancer (PC) is the fourth leading cause of cancer-related deaths in the
U.S., claiming approximately 45,000 lives every year. Much like other solid tumors, PC
evades the host immune system and establishes itself by manipulating the immune
system to establish an immunosuppressive tumor microenvironment (TME). Therefore,
targeting and reinstating patient’s immune system could serve as a powerful therapeutic
tool. Indeed, immunotherapy has emerged in recent years as a potential adjunct treatment
for solid tumors including PC. Immunotherapy modulates the host’s immune response to
tumor-associated antigens (TAAs), eradicates cancer cells by reducing host tolerance
against TAAs and provides both short- and long-term protection against the disease.
Passive immunotherapy like monoclonal antibodies or adoptive T-cell based therapy
focuses on direct targeting of tumor cells, whereas, active immunotherapy like cancer
vaccines specifically activates the patient’s immune cells against cancer cells. Such
strategies have been tested for antitumor responses alone and in combination with
standard care in multiple preclinical and clinical studies. In this review, we discuss various
immunotherapy strategies used currently and their efficacy in abrogating self-antigen
tolerance and immunosuppression, as well as their ability to eradicate PC.
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2. Introduction to Immunotherapy
It's forecasted that by 2030, pancreatic cancer (PC) will become the second
leading cause of cancer-related deaths in the United States [1]. The current overall
survival of PC patients by stage of disease progression is no more than 14% at Stage I,
and the overall 5-year survival is approximately 8% [2]. The success rate of various
treatment modalities for PC including surgery, chemotherapy, and radiation is limited and
reoccurrence is typically inevitable [3]. In addition, late diagnosis of the disease further
compounds the problem leading to high mortality rate. Recently immunotherapy has
revolutionized cancer treatment especially in melanoma [4, 5]. It is increasingly being felt
that immunotherapy if applied properly in combination with the standard of care can lead
to better outcomes in solid tumors including PC. Studies support immunotherapy as a
viable and metamorphic approach, which can boost and restore the immune system’s
ability to fight against cancer.
In this review, we describe the current understanding of different immunotherapeutic
approaches including anti-cancer monoclonal antibodies (mAbs), T-cell-mediated
immunotherapies and cancer vaccines, as powerful strategies for PC treatment. We will
also discuss the clinical efficacy of immunotherapeutic strategies, challenges and assess
their feasibility as next-generation treatment options, either alone or in combination with
chemotherapy for PC treatment.

3. Immunoediting and Immunosuppressive Microenvironment
The interaction of the immune system with cancer cells is comprised of the three
phases: Elimination, Equilibrium and Escape [6-8]. During the Elimination phase, the
immune system can recognize and eliminate transformed cells. PC cells shed MICA that
impairs cell surface expression of NKG2D receptor on T-cell and Natural Killer (NK) cells,
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thus, helping tumor cells to escape immune surveillance by inhibiting the cytolytic activity
of T-cell and NK cells [9, 10]. Transformed cells that escape the Elimination phase enter
the Equilibrium phase, in which cancer cells undergo genomic editing and establish the
tumor microenvironment (TME) that supports the growth of the early lesions. Finally, in
the Escape phase, PC recruit immunosuppressive cells like myeloid-derived-suppressor
cells (MDSCs), regulatory T-cells (Treg cells) and tumor-associated macrophages (TAMs)
[11, 12]. These immature MDSCs induce apoptosis in activated T-cells. Depletion of
MDSCs in an autochthonous PC mouse model results in the unmasking of adaptive
immune responses, tumor cell death and remodeling of tumor stroma [13, 14]. PC
conditioned media-treated CD4+ T-cells favored expansion of CD69+ activated Treg subset,
which is known to suppress CD4+ T-cell proliferation, thus promoting immunosuppression
[15].
PC tumor and stromal cells secrete angiogenic chemokines like vascular
endothelial growth factor (VEGF), signaling molecules like galectin-1 (GAL-1) [16], antiinflammatory cytokines like Interleukin (IL)-10, IL-13 [17], and immune-inhibitory ligands
like programmed death ligand 1 (PD-L1), cytotoxic T-lymphocyte-associated protein 4
(CTLA-4), which further facilitate escape from cytotoxic cell-mediated death by cluster of

differentiation (CD)8+ T-cells and NK cells

[13, 14, 18-22] (Figure 1). Additionally,

exhausted CD8+ T-cells have chromatin-accessible-regions (ChARs) that serve as an
enhancer to maintain high levels of programmed cell death protein 1 (PD-1), which further
keeps CD8+ T-cells in an immunosuppressive state [23]. After escaping the
immunosurveillance, immunologically and genetically modified tumor cells proliferate,
which further prevent immunological [6, 8, 24]. Overall, cancer cells modify itself
genetically and exploit the immunosuppressive behavior of the immune system to facilitate
its escape from cell death mediated by CD8+ T lymphocytes and NK cells.
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4. PC Microenvironment and Immune Suppression
PC cells harbor limited genetic alterations and simultaneously modulate the TME to
escape antitumor immune response. Several studies suggest that immunotherapeutic
approaches are more effective in cancers with high mutation profile, displaying varied
neoantigens, and having permeable tumor matrix architecture allowing better effector
CD8+ T-cell infiltration [25, 26]. Furthermore, PC is an immunologically ‘cold’ tumor due to
its low mutational load, dense desmoplasia and rigid extracellular matrix architecture,
which restricts the access of effector immune cells to tumor islands, a phenomenon known
as excluded infiltrate TME [27-31].
Activated PC stromal compartment excludes CD8+ T-cells, CD20+ B-cells, and
CD56+ NK cells from the juxtatumoral region of the tumor. Administration of all-trans
retinoic acid in a spontaneous K-rasLSL.G12D/+; p53R172H/+; Pdx-1Cre mice (KPC) mouse
model induced quiescence in stromal cells, reduced fibronectin expression and
correspondingly increased high influx of CD8+ T-cells into juxtatumoral compartment [32].
In PC tumor-bearing transgenic mice, ~55% of fibroblast activation protein-positive (FAP+)
stromal cells were depleted by selective expression of the diphtheria toxin receptor,
showed slow tumor growth only in the presence of CD4+ and CD8+ T-cells in the TME.
Administration of anti PD1 and anti CTLA-4 antibodies along with FAP+ stromal cell
deletion further reduced tumor growth in these mice [33]. Jiang et al. targeted focal
adhesion kinase (FAK) using a selective FAK inhibitor VS-4718 and observed reduced
tumor fibrosis and significantly increased survival of KPC mice, compared to untreated
control mice. The authors demonstrated that FAK was hyperactive in neoplastic PC tumor
and contributed to immunosuppressive TME by restricting cytotoxic CD8+ T-cells
infiltration. Inhibition of FAK made TME penetrable, which increased adoptive cytotoxic
anti-ovalbumin (OVA) CD8+ T-cells infiltration in the tumor and the efficacy of PD-1
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antagonists in KPC mice when combined with low dose gemcitabine (25mg/kg) compared
to combined treatment with vehicle, gemcitabine and anti PD-1 antibody [34]. These
studies suggest that the presence of stroma in PC adds an obstacle to current
immunotherapy strategies.
Modulation of stromal cells and their effects are influenced by galectins, which are
soluble immune-modulating glycoproteins involved in T-cell homeostasis. For example,
GAL-1 is expressed primarily by pancreatic stellate cells (PSCs), and GAL-1
overexpressing PSCs have been shown to induce apoptosis in co-cultured CD4+ and
CD8+ T-cells compared to normal or quiescent PSCs [35, 36]. Another member of the
galectin family, Galectin3 (Gal3), has also been demonstrated to play an important role in
CD8+ T-cell biology by inducing the apoptosis in activated T-cells [37, 38]. Jaffee et al.
found that neu-specific CD8+ T-cells have a high surface expression of lymphocyte
activation gene 3 (LAG3), and Gal3 interaction with LAG3 induces immunosuppressive
signaling in T-cells through the Gal3-LAG3 axis. This interaction reduces Interferon γ
(IFNγ) production by CD8+ T-cells and abrogates their infiltration into the TME [39].
Immunization

with

GM-CSF/neu

(granulocyte-macrophage

colony-stimulating

factor/neu) vaccine has higher efficacy in Gal3 knockout tumor-bearing mice when
compared to wild-type tumor-bearing mice. After 60 days of treatment, approximately 80%
of Gal-3-knockout mice were disease free, compared to 20% of wild-type mice. Neuspecific CD8+ T-cells produced high amounts of interferon-gamma (IFNγ) and granzyme
B. In addition, Gal3 knockout mice had increased infiltration of plasmacytoid dendritic cells
(DCs), which have a higher potential to activate CD8+ T-cells than conventional DCs.
Thus, galectins play an important role not only in modulating T-cell function but also in the
recruitment of immunosuppressive myeloid-derived suppressor cells (MDSCs) [39].
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Apart from the establishment of stroma, tumor cells also modulate the cellular
composition of their microenvironment. Tumor-associated macrophages (TAMs), which
are M2 (pro-tumor) differentiated macrophages, express tolerance-inducing ligands such
as PD-L1/L2, promote angiogenesis, and suppress adaptive immune responses through
matrix remodeling carried out by matrix-metallopeptidases (MMPs) [40]. In addition,
immunosuppressive CD4+FOXP3+ Treg cells heavily infiltrate human PC tumors. In the
KPC mouse model Treg infiltration increases during the progression from pancreatic
intraepithelial neoplasm (PanIN) to the advanced PC stage [13]. Similarly, increased
numbers of CD68+ TAMs and MDSCs in circulation and TME are associated with disease
invasiveness in PC patients [41, 42]. MDSCs also produce reactive oxygen species that
further inhibit the antigen-specific response of CD8+ T-cells in TME [43].
PC tumor cells secrete anti-inflammatory cytokines and angiogenic chemokines
that promote an immunosuppressive TME while facilitating metastasis [3, 32, 41, 44].
These cytokines activate Treg and Th2 cells that prohibit anti-tumor responses elicited by
other immune cells [24, 45-47]. Likewise, Indoleamine 2, 3-dioxygenase (IDO) enzyme is
secreted by PC tumor cells that upregulate the growth of tumor cells by catabolizing
tryptophan into kynurenine, and in turn inhibits T-cell and NK cells activation as well as
induces Treg differentiation leading to immunosuppressive TME [3].
Cytotoxic T-cells (CTLs), helper T-cells and DCs are functionally impaired in the
immunosuppressive TME of PC, thus skewing to Th2 (tumor-tolerating) responses.
Therefore, a proper understanding of these intricate cancer-immune system interactions
is very essential to develop and monitor efficacious immunotherapies. The primary goal
of PC immunotherapies is to target these interactions and the reprogramming of the
immune system against PC tumor microenvironment
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5. Immunotherapy Based Approaches
The goal of immunotherapy is to induce antitumor responses by reprogramming and
augmenting immune surveillance and removing immune suppression. These anti-cancer
immunotherapeutic approaches are divided into ‘passive’ and ‘active’ immunotherapies.
Passive immunotherapeutic strategies involve mAbs, adoptive T-cell transfers and
genetically engineered T-cells. Whereas the active immunotherapeutic approaches
include vaccine-mediated immunity induced by the administration of tumor-associated
antigens (TAAs) [48]. The TAAs could be delivered in the form of DNA or peptide vaccines,
as well as modified tumor cells or antigen-pulsed DCs. Due to genetic alterations or posttranslational modifications of proteins (such as glycosylation, phosphorylation, etc.), tumor
cells can express proteins that differ from their counterpart in the normal cells or are
aberrantly overexpressed in tumor tissues [49].

5.1 Passive Immunotherapeutic Strategies
Passive immunotherapy attacks cancer by directly targeting TAAs by the
administration of diverse immune components that are engineered ex vivo. Following are
the major passive immunotherapeutic strategies ongoing in preclinical studies or clinical
trials and have been summarized in Table II.
5.1.1

Antibody-Mediated Passive Immunotherapy

Antibody-mediated immunotherapy involves targeting tumors using monoclonal
antibodies

(mAbs),

antibody

fragments,

antibody-drug

conjugates,

or

radio-

immunotherapy conjugates to inhibit tumor signaling, immune suppression, or immune
checkpoint blockade.
Anti CD40 mAbs
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CD40 is a member of the tumor necrosis factor (TNF) receptor superfamily and is
expressed primarily on APCs such as DCs, macrophages, monocytes, B-cells and some
non-immune cells like cancer cells [50]. Anti-CD40 antibodies mimic the co-stimulatory
signal of the CD40 ligand (CD40L). Tumor-bearing KPC mice with constitutive K-ras
activation and gain-of-function p53 mutation when treated with anti-CD40 (clone FGK45,
endotoxin-free), either alone or in combination with gemcitabine, showed detectable tumor
regression. Treatment with anti-CD40 mAb bypassed the requirement for Toll-Like
Receptors (TLRs), inflammasome, Type I interferons (IFNs), and stimulator of interferon
genes (STING) to effectively prime adaptive T-cell responses against PC in these animals
[51]. The mechanistic role of agonistic anti-CD40 mAb is to activate host antigen
presenting cells (APCs) especially DCs, and also to induce clinically relevant antitumor Tcell responses, reverse tumor-induced immune suppression and induce T-cellindependent but macrophage-dependent tumor regression in PC patients [52]. In a clinical
trial, 22 naïve patients with advanced PC were administered weekly doses of anti-CD40
mAb in combination with gemcitabine, which led to the increased B-cell surface expression
of co-stimulatory molecules CD86, HLA-DR, and CD54 at 24-48 h post-treatment [52-55].
In another study on 21 chemotherapy-naϊve and surgically incurable PC patients,
treatment with gemcitabine and a human agonist anti-CD40 mAb (CP-870,893) for three
weekly cycles showed the enhanced overall survival of 7.4 months compared to those
who received gemcitabine alone with the median overall survival of 5.7 months. Upon
biopsy, the tumors of anti-CD40 mAb-treated patients showed higher infiltration of
macrophages, however, with accompanying absence of lymphocytes [55, 56].
Anti PD-L1mAbs
PD-1 (CD279) is a T-cell co-inhibitory receptor expressed on the surface of
activated T-cells, Tregs and monocytes had extensively been exploited for immunotherapy.
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PD-1 on T-cells interacts with two B7 family ligands, PD-L1 (CD274) and PD-L2 (CD273)
expressed on tumor cells that leads to T-cell anergy or death and thus leading to tumor
survival [57]. Presence of infiltrating PD-1+ T-cells in densely or loosely desmoplastic
pancreatic tumors suggests tumor antigen-specific T-cell activation that correlates with
increased overall survival, progression-free survival and distant-metastasis-free survival
of PC patients [58]. Activated T lymphocytes infiltrating the TME express inflammatory
cytokines like IFNγ that further stimulates PD-L1/L2 expression in the tumor cells [59, 60].
Blockade of PD-1 by an mAb abrogates the PD-1/PD-L1 axis and restore T-cell cytotoxic
function [61]. In a preclinical study, combined treatment of Panc02 tumor-bearing mice
with anti-PD-L1 mAb and gemcitabine significantly reduced average tumor volumes
compared to gemcitabine and anti-PD-L1 mAb alone [62]. Due to the relative success of
anti-PD-1 antibodies in both preclinical and clinical studies on selective solid tumors, the
FDA recently approved two anti-PD-1 antibodies, pembrolizumab and nivolumab, for head
and neck cancer, renal, melanoma, and non-small cell lung cancer treatment [63, 64].
Anti CTLA-4 mAbs
CTLA-4 is another co-inhibitory molecule expressed on the surface of activated Tcells and Treg cells. CTLA-4 present on T-cells interacts with B7-1/B7-2 ligands on APCs,
resulting in depletion and suppression of CD68-mediated T-cell-activation [65].
Ipilimumab, an antagonist mAb against CTLA-4, inhibits immunosuppression by Treg cells
and enhances the antitumor activity of effector T lymphocytes and innate immune cells. In
a preclinical study, in-vitro treatment with ipilimumab significantly enhanced T-cell
proliferation (preferentially promoting CD8+ T-cell expansion), Th1 cytokines release
(IFNγ, IL-2, and IL-12), and increased cytotoxicity of CD8+ T-cells against Colo356/FG PC
cells [66, 67]. In a Phase Ib clinical trial, patients with previously treated or histologically
proven PC were given ipilimumab alone or in combination with GVAX. Post-treatment,
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both the single and combination treatments enhanced mesothelin (MSLN) specificCD8+
T-cell populations that correlated with increased survival of >4.3 months, as well as a
decline in CA-19.9 levels in 7 out of 15 patients compared to patients treated with
ipilimumab alone (0 out of 15 patients) [68]. Combination therapy of anti-CD40, anti-CTLA4 and anti-PD-1 antibodies with chemotherapy/nab-paclitaxel in KPC mice resulted in
tumor regression in 39% of the animals (17 out of 44 mice), along with increased CD8+ Tcell infiltration and reduction in Treg cells (7-fold CD8: Treg ratio) in the PC TME.
Furthermore, PC tumor cells implanted on the opposite flank were rejected with no
additional treatment in 67-86% of mice, suggesting the development of immunological
memory [69].
Other targeted therapy antibodies
Additionally, antibodies like cetuximab, pertuzumab, and trastuzumab that bind to
the extracellular domain of the human epidermal growth factor receptor 1 (HER1)/
epidermal growth factor receptor (EGFR) and inhibit their dimerization and internalization
are under clinical investigation [70, 71]. In Phase II and III clinical studies, patients with
metastatic PC were administered cetuximab in combination with gemcitabine leading to a
stable disease in 63.4% of PC patients and a partial response in 12.2% of patients
however there was no increase in the median overall survival of metastatic PC patients.
[72]. Contrarily in IMPaCT clinical trial using next-generation sequencing technologies,
personalized treatment of 5 PC patient’s tumors with human epidermal growth factor
receptor 2 (HER2) amplification with trastuzumab showed no successful outcome [73].
Similarly, another Phase II clinical trial showed no responses in 33 advanced PC patients
treated with trastuzumab (3.0 or 4.0 mg/kg then 1.5 or 2mg/kg, weekly) and cetuximab
(400mg/m2 and then 250mg/m2) [74].
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Scales et al., developed an anti-mesothelin (anti-MSLN) antibody to the unfolded,
non-glycosylated MSLN extracellular domain and conjugated it to the microtubuledisrupting drug monomethyl auristatin E (MMAE). Humanized versions of anti-mesothelin
(MSLN)-MMAE induced regression of MSLN-expressing HPAC xenografts in nude mice
with a doubling delay to ≥74 days. Due to its robust and durable efficacy in mouse models,
humanized anti-MSLN-MMAE is in Phase I clinical trials for PC [75]. Similarly, a Phase II
clinical trial with the VEGF antibody bevacizumab in 19 out of 30 patients showed stable
disease and partial response in 1 patient, although the antibody treatment alone did not
improve the overall survival of patients [76].
MDSCs are known to secrete tumor-promoting factors, such as prokineticin 2
(PK2/Bv8). Anti-Bv8 antibody targeting the extracellular domain of Bv8 given in
combination with gemcitabine reduced growth of orthotopic metastatic PC tumors,
significantly reduced MDSCs infiltration, hypoxia and angiogenesis compared to mice
treated with gemcitabine alone, indicating the significant potential of the anti-Bv8 antibody
as a combinatorial or post-chemotherapy treatment in PC patients [77]. PC cells express
antigens that are either unique to cancer or are being shared with other cancers with
similar epithelial origin. The widely studied TAAs of PC that are currently utilized in
vaccines in clinical trials are listed in Table I.

5.1.2 Passive T-cell-Mediated Immunotherapy
Monoclonal antibody (mAbs) based targeted therapy can elicit direct killing of
tumor cells but has not provided long-term benefit to PC patients. Multiple studies are
evaluating the strategies to develop passive T-cell-mediated immunotherapies including
increasing the number of antigen-specific CD8+ T-cells, the responsiveness of the antigenspecific T-cells, or the affinity of the antigen-specific T-cell receptor (TCR) (e.g., with
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transfected TCRs). Additional summary regarding the current clinical trials utilizing these
strategies is provided in Table III.
a) Adoptive T-cell transfer (ACT)
The primary objective of ACT therapy is to isolate and expand T-cells ex vivo and
transfer these autologous lymphocytes with antitumor activity in cancer patients. This
method leads to the expansion of antitumor T-cell populations in the patient resulting in
increased cytokine release and tumor cell targeting.
Kawaoka et al., developed CTLs by isolating T-cells from the blood of healthy
volunteers expressing human leukocyte antigen (HLA)-A phenotype 24/26 and stimulating
them with the MUC1-expressing human PC cell line YPK-1 (HLA-A phenotype 24/02) in
combination with IL-2. The MUC1-specific CTLs killed five MUC1-expressing PC cell lines,
irrespective of their HLA phenotype. 20 patients with either non-resectable or resectable
PC were treated with MUC1-specific CTLs. Patients with non-resectable tumor did not
show any improvement (median survival time (MST) of 5 months), however, 18 out of 20
patients with resectable PC responded with an MST of 17.8 months [78].
Murine PC cell lines have significant overexpression of telomerase activity.
C57BL/6 mice were immunized with H2b-restricted telomerase peptide emulsified with
incomplete Freund’s adjuvant, in complex with macrophage-activating lipopeptide-2
(MALP-2, a Toll-like receptor 2/6 agonist) to drive the generation of telomerase-specific
CTLs. Orthotopically implanted syngeneic tumor-bearing mice were treated with IL-2expanded anti-telomerase CTLs, which significantly reduced tumor volume compared to
untreated mice. In addition, anti-telomerase CTL-treated mice developed higher numbers
of both CD8+ central memory and effector antigen-specific T-cells [79]. Furthermore, in a
clinical study, 46 PC patients with non-resectable and recurrent tumors received anti-CD3stimulated lymphokine-activated killer (CD3-LAK) therapy (25 patients) or RetroNectinVR

14
(CH296)-induced T-cell (RIT) therapy (21 patients) at 2-week intervals. The ACT treated
patients showed an increased circulating levels of IFNγ, IL-12, and IL-2, suggesting that
the combined circulatory levels of these cytokines may serve as a predictive marker of the
clinical response to ACT in patients [80].
b) Chimeric antigen receptors (CAR) T-cells
Highly antigen-specific autologous T-cells that are genetically engineered to
express tumor antigen-specific TCRs or immunoglobulin-based fusion proteins are known
as chimeric antigen receptors (CAR) T-cells. These engineered CAR T-cells are then
cultured and expanded ex vivo for therapeutic purposes (Figure 2).
The differential glycosylation pattern of mucins provides a unique repertoire of
antigenic epitopes that can be exploited for developing tumor-specific CAR T-cells. Posey
et al. designed a scFv of a high-affinity antibody (5E5) to detect truncated O-glycopeptide
MUC1 epitopes (GSTAP with one or two Tn O-glycans on the Ser/Thr residues) that are
not expressed in normal tissues. MUC1 CAR T-cells (composed of 5E5 mAb scFV on a
CAR backbone of CD8α, transmembrane domain and costimulatory domains of 4-1BB
and CD3ζ) were generated that target the Tn/STn glycopeptide epitope on MUC1, and
upon recognition of MUC1-9Tn, secreted high quantities of IL-2 and IFNγ, but not in
response to the non-glycosylated MUC1-60-mer. Hs766T pancreatic tumor-bearing mice
when treated with 5E5 CAR T-cells showed potent responses and improved survival to
113 days with 100% animals surviving compared to 40% and 33% of mice treated with
non-transduced and CD19 CAR T-cells, respectively. In addition, many 5E5 CAR T-cells
specifically accumulated in Hs766T tumors, in contrast to a small percentage of CD19
CAR T-cells [81, 82].
Carcinoembryonic antigen (CEA) is highly overexpressed on the surface of PC
cells. Murine CEA binding domain (SCA431scFv)-containing CAR T-cells with intracellular
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CD28-CD3 signaling domain were adoptively transferred into Panc02 CEA+ tumor-bearing
CEA transgenic mice. Anti-CEA CAR T-cells significantly reduced the size of pancreatic
tumors and produced long-term tumor elimination in 67% of the mice without inducing an
autoimmune reaction. Upon re-challenge with CEA+ C15A3 cells, the animals rejected the
cells and demonstrated increased serum levels of IL-1β and IL-5 [83]. A similar study
reported the eradication of CEA+ tumors in CEA-transgenic mice as a primary response
to anti-CEA CAR T-cells with CD3ζ endo-domain and rejection of CEA+ PC cells upon rechallenge. Based on the CAR T-cell model, there is evidence that antigen-specific CD8+
T-cells can be induced to overcome self-tolerance and eliminate cancer cells while sparing
normal cells [84].
Prostate stem cell antigen (PSCA) is another highly expressed TAAs in PC
patients as well as in tumor-derived cell lines. In a recent study, PSCA-specific CAR Tcells showed specific targeting and lysing of PSCA-expressing PC cells (ASPC1, Capan1) while PSCA-negative 293T-cells showed no cytotoxicity [85]. In another study, antiPSCA CAR T-cells were engineered using antigen-recognition domains derived from
mouse or human antibodies with either one (CD28) or two (CD28 + 4-1BB) T-cell costimulatory molecules linked to the CD3ζ endo-domain. These anti-PSCA CAR T-cells
elicited antitumor responses in established human PC-derived xenograft tumors and 2 out
of 5 mice showed complete tumor eradication [86].
MSLN is highly overexpressed on PC cells compared to its negligible expression
in normal pancreas. Hingorani et al. developed MSLN peptide-specific high-affinity
TCR1045 expressing CD8+ CAR T-cells that lysed KPC tumor cells in vitro and secreted
IFNγ upon antigen recognition. A study in KPC mice showed that TCR1045 CAR T-cells
infiltrated the pancreatic tumors four days post-injection and induced apoptosis of cancer
cells after eight days of infusion. Upon the second infusion, TCR1045 CAR T-cells showed
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10-fold increased retention in pancreatic tumor compared to non-specific (TCRgag) T-cells.
However, mice in both treatment groups developed progressive disease. TCR1045 cell
recipient mice showed less metastasis (46%) and overall survival of 96 days compared to
64% metastatic lesions and survival of 54 days in TCRgag treated mice. Overall, these data
suggest that tumor antigen-specific engineered T-cell therapies are viable options for the
treatment of invasive PC [87].

5.2 Active Immunotherapeutic Strategies
Active immunotherapy relies on stimulation of the immune system through
immunological recognition of TAAs by T and B lymphocytes. TAAs have been widely
explored as cancer vaccines for the treatment of PC in both in vivo mouse models and
clinical trials. Cancer vaccines can be whole cancer cell-based vaccines, antigenic-peptide
pulsed vaccines or DC-based vaccines. These vaccines are developed to exploit and
activate both innate and active immune arms to eradicate tumor cells and evade future
recurrence of the disease. Cancer vaccines currently being investigated in clinical trials in
PC are summarized in Table IV.
5.2.1

Cancer Vaccines

Mucin (MUC) Vaccines
Mucins (MUCs) are glycoproteins that are differentially overexpressed in
pancreatic tumor but is absent in normal pancreas. Some mucins (e.g., MUC1 and MUC4)
have also been demonstrated to contribute to chemoresistance, and to enhance
proliferation and survival of PC cells [88]. Therefore, mucins are being studied as potential
candidates for vaccine development for PC. Studies conducted in human MUC1transgenic (MUC1.Tg) mice treated with MUC1 cancer vaccines failed to show any
detectable responses against MUC1+ tumor cells despite, MUC1-specific T-cells
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generating IFNγ, IL-4 and IL-10 cytokines. The immune responses in these mice were not
skewed to either type 1 or type 2 immune response thus rendering the vaccine ineffective
against the B16.MUC1 tumor.[89]. The CD8+ T-cell killing of MUC1-expressing tumor cells
was found to be mediated by perforin and FasL cytolytic pathways. Also, lymphotoxin-α,
but not TNF receptor-1 (TNFR-1), played a critical and non-redundant role in the cellmediated rejection of MUC1 expressing tumor cells [90]. In a Phase I clinical trial, MUC1peptide (GVTSAPDTRPAPGSTAPPAH)-pulsed DC vaccines were administered to 7
patients with advanced PC. 2 out of 7 patients showed significantly increased mature DCs
and peripheral blood mononuclear cell (PBMC)-mediated immune responses that were
characterized by high IL-12p40 and IFNγ secretion, respectively. However, there was no
tumor rejection in these patients [91]. A similar Phase I clinical trial in 20 advanced PC
patients was performed with MUC1 peptide-pulsed DCs in combination with MUC1specific CTLs. One patient with lung metastases showed complete remission, while five
other patients demonstrated stable disease for at least six months post-therapy [92]. A
study was conducted with 6 PC metastatic patient-derived DCs that were co-transfected
with MUC4 and survivin mRNAs. These mRNA-loaded DCs activated CTLs against the
MUC4 protein. Anti-MUC4 CTLs effectively targeted a human PC cell line (Capan-2) via
major-histocompatibility-complex-I (MHC-I)-restricted recognition and released IFNγ.
MUC4-mRNA-pulsed DCs stimulated more CTLs than survivin-mRNA-pulsed DCs, but
comparatively elicited fewer CTLs activated by MUC4-survivin-mRNA-loaded DCs [93]. In
another study, mature DCs were pulsed with a MUC4 epitope peptide (LLGVGTFVV) and
co-cultured with CD8+ T-cells to generate MUC4-specific CTLs that could effectively kill
HCT-116 colorectal cancer cells (MUC4+, HLA-A2+). However, the intensity of MUC4
surface expression on PC cell-line HPAC proportionally increased the apoptosis of MUC4specific T-cells, thus rendering the therapy ineffective [94]. Based on these studies, other
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mucins like MUC5AC, and MUC16 that are significantly overexpressed in PC may serve
as potential vaccine candidates to develop novel immunotherapies.
Telomerase Vaccines
Due to overexpression of telomerase in PC patients, cancer vaccine containing
telomerase-derived peptide (GV1001) vaccine is under clinical studies. However, so far
PC patients treated with a combination of the GV1001 vaccine, GM-CSF, and gemcitabine
showed transitory and weak Th1-type immune response, reduced infiltration of Treg cells,
and no significant increase in median overall survival. In a related clinical trial, the GV1001
vaccine failed to enhance the effects of chemotherapy (gemcitabine and capecitabine)
[95, 96].
CEA Vaccines
CEA is overexpressed in >90% of PC patients making it a potential
immunotherapeutic target. A Phase I clinical trial with CAP1-6D, an altered CEA peptide
ligand/Montanide/GM-CSF vaccine, administered to 66 PC patients elicited robust CD8+
T-cell-mediated. In addition, 8 of the patients were found to have high IFNγ production, of
which four patients showed progressive disease, three patients had stable disease, and
one patient showed a complete response [97].
KIF20A Vaccines
Another cancer vaccine candidate is kinesin-like protein 20A (KIF20A), a member
of the kinesin super family, which is significantly upregulated in PC. KIF20A-66, an HLAA24-restricted epitope peptide derived from KIF20A peptide vaccine was injected into 29
PC patients in Phase II clinical trial. The tumor size (as confirmed by CT scan) was
reduced in 8 patients and 16 patients showed increased CTL responses, which correlated
with the increased overall survival of vaccinated patients [98]. In a similar Phase I trial,
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nine advanced PC patients who previously received chemo/radiotherapy were treated with
KIF20A-10-66 (KVYLRVRPLL) peptide vaccine along with gemcitabine. These patients
showed increased activation of KIF20A-specific IFNγ-producing T-cells, had stable
diseases and longer overall survival, indicating that KIF20A-based vaccines are possible
immunotherapy candidates for PC [99].
K-ras Vaccines
K-ras is mutated in the majority of PC patients and is currently under investigation
as an immunotherapy target. Inactivation of the oncogenic mutant K-ras enhances MHC I
presentation [100]. In an in vivo study, mice were treated with lysates of human PANC-1
PC cells expressing mutant K-ras, with lysate in combination with K-ras mutant peptide
(K-ras+peptide), or with lysate and peptide plus cationic nanoparticles (CNP)
encapsulating K-ras mutant peptide (K-ras+peptide-CNP). The K-ras+peptide-CNP
activated CTLs induced specific killing of K-ras-positive tumors efficiently and improved
the survival time of K-ras mutant tumor-bearing nude mice compared to the K-ras mutant
lysate and K-ras peptide treatment group (132). In addition, a clinical trial testing a mutant
Ras peptide vaccine (administered in combination with GM-CSF) in 11 patients with
advanced PC showed higher antitumor responses (92% exhibiting an immune response)
with two patients having a complete response and overall survival of 20.8 months [101,
102].
WT1 Vaccines
The Wilm’s Tumor protein 1 (WT1) is another suitable vaccine target for PC due
to its differential overexpression in tumor cells but not in the normal pancreas [103]. In a
recent study, 32 HLA-A*24:02+ advanced PC patients were treated with an HLA-A*24:02restricted, modified 9-mer WT1 peptide (CYTWNQMNL) emulsified with Montanide ISA51
adjuvant (WT1 vaccine). The MST of patients who responded to the WT1 vaccine was
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10.9 months. Further, these patients developed strong effector T-cell responses along
with generation of WT1-specific CD8+ memory T-cells, whereas unresponsive patients
showed MST of only 3.9 months [104]. In a separate clinical trial, nine patients with
advanced PC were vaccinated with WT1 peptide vaccine and 8 out of 9 patients
demonstrated stable disease. However, no WT1-specific T-cells were observed in the
circulation of these patients [105].
VEGF Vaccines
VEGF is another protein that is overexpressed in PC. In a trial, nine advanced PC
patients were vaccinated with four peptides comprised of KIF20A, cell division cycleassociated 1 (CDCA1), VEGFR1, and VEGFR2. Patients demonstrated increased antiCDCA1 and anti-VEGFR2 CD8+ T-cells in circulation. Additionally, 4 out of 9 patients
presented with stable disease post-vaccination [106]. In a subsequent study, vaccination
with WT1 and VEGFR2 peptides generated HLA-A24-restricted CTLs, which
demonstrated strong cytotoxicity towards PC cells that were HLA-A24-positive and
expressed corresponding TAAs [107].
Prophylactic Cancer Vaccines
Prophylactic vaccines have recently been investigated as immunotherapy tools to
target endogenous neoantigens by utilizing attenuated bacteria/virus to stimulate
antitumor adaptive immune responses [108]. Listeria monocytogenes (LM) is a grampositive bacterium that induces robust CD4+ and CD8+ T-cell responses by its selective
infection of APCs (via actA virulence gene) over non-phagocytic cells (inlB gene). An LM
ΔactA/ΔinlB strain engineered to express human MSLN (CRS-207 vaccine) was
administered to 10 PC patients, which resulted in induction of expression of Th1 cytokines
(IL-12, TNF-α). In addition, 6 out of the 10 patients developed MSLN-specific CD8+ T-cells
[109, 110]. Jaffee et al. conducted a clinical trial on 93 metastatic PC patients, in which 69
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patients received two doses of cyclophosphamide with GVAX (Cy/GVAX) followed by four
doses of CRS207 (Arm A) and 21 patients received six doses of Cy/GVAX (Arm B).
Patients in Arm A showed increased overall survival of 9.7 months compared to 4.6
months inArm B, suggesting that the success of this immunotherapy might depend on the
proper patient selection [111]. The KrasG12D oncogene prophylactic vaccine (LM-K-ras
vaccine) has been studied in KPC mice, either alone or in combination with Treg depletion
(anti-CD25 antibody, PC61, and low-dose Cy). KPC mice that received the vaccine at
early PanIN 1 stages in combination with Treg depletion showed prolonged survival
compared to mice that received the vaccine alone at either early or late PanINs stage,
suggesting the potential of Treg depletion therapy as the prophylactic approach for PC
[112].
STING activation as an adjuvant to vaccines and other immunotherapies
STING is a transmembrane protein that resides on the endoplasmic reticulum,
which upon activation through cyclic dinucleotides (CDNs), synthetic CDNs, or bacterial
infection in the host induces interferon beta (IFNβ) and nuclear factor kappa-light-chainenhancer of activated B cells (NF-κB) pro-inflammatory responses via IRF3 and Stat6
pathways [113]. It has been shown that endogenous STING activation via CDNs in the
tumor microenvironment enhanced inflammatory responses, thereby inhibiting tumor
progression and distant metastasis [114]. Recently, intraperitoneal injection of DMXAA,
an activator of the mouse STING pathway, activated CD8+ T-cells that led to tumor
rejection [114, 115]. Similarly, synthetic STING activators known as RR-CDGs have
shown efficacy in the regression of primary pancreatic tumors, and distant metastatic
lesions through T-cells recruitment in a TNF-α-dependent manner [116]. Furthermore,
these novel synthetic activators of STING have demonstrated enhanced adjuvant activity
to accelerate adoptive immune responses in the presence of radiation therapy [116]. The
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cGAMP-induced activation of endothelial cell-specific STING enhanced the antitumor
responses of CD8+ T-cells and improved the responses of anti-CTLA-4 and anti-PD-1
immunotherapies [117].

6. Challenges in Pancreatic Cancer (PC) Immunotherapy
The immune system has the potential to selectively target tumor cells upon
strategic activation in cancer patients leading to better therapeutic outcomes. However,
tumors employ extensive measures to escape immune surveillance, suggesting the
necessity to develop novel counteracting strategies for the improved efficacy. Therefore,
recent immunotherapeutic approaches alone or in combination with conventional
treatment modalities need to be re-evaluated for successful therapeutic outcome in terms
of improved patient survival.

6.1 Identification of Tumor Associated Antigens for PC Immunotherapy
Tumor-associated antigens are autologous cellular antigens that are specifically
expressed by cancer cells and are negligibly expressed by or absent in normal cells.
Mutation-derived tumor antigens are generated by somatic mutations inherited by tumor
cells during malignant transformation that may be identified by immune surveillance [118].
The Cancer Genome Atlas (TCGA) database analysis showed that notably PC afflicted
patients carry limited genetic mutations between 4 to 4000 neoantigens [119, 120]. When
compared to melanoma patients who could likely express 14000 neoantigens that is a
significantly low number of neoantigen repertoire in PC patients. Further expression
neoantigens mutation load correlated negatively with T-cell tumor infiltration and
corresponding overall survival of PC patients [119]. Differentially and spatiotemporally
overexpressed or post-translationally antigens could potentially serve as tumor antigens
for immunotherapy purposes [121]. A preferred way utilized to validate the likelihood of
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these tumor antigens to be immunogenic in patients, is to detect autoantibodies against
them in cancer patient serums and this strategy has met with moderate success [122,
123]. Multiple proteins like mucins (MUC1), WT1, VEGF, etc. overexpressed in PC
patients, have been extensively exploited for PC immunotherapy but have achieved
limited success as discussed previously in the review. It has been challenging to identify
eligible TAAs and thus, necessitates coming up with a strategy to discover novel tumor
antigen that could be targeted efficaciously by immunotherapy in PC patients.

6.2 Generation of Anti-Tumor Responses Against PC Microenvironment
Strong immunosuppressive TME, rigid tumor matrix architecture, T regs infiltration,
constant antigen exposure mediated T-cell exhaustion, and upregulation of inhibitory
receptors like PD-1 provide physical obstacles to effector T-cells function and generates
tolerance towards tumors [124, 125]. Thus, checkpoint inhibitors and depletion of Tregs
could potentially reverse T-cell exhaustion of effector T-cells. Improper homing and
inefficient infiltration of CAR T-cells to the tumor bed occur due to tumor blood vessels not
responding to inflammatory stimuli. Anti-angiogenic therapy matures tumor blood vessels,
facilitating pericyte recruitment and increasing tumor perfusion, which consequently
increases the efficacy of CAR T-cell immunotherapy [126]. Apart from improper homing,
CARs recognize TAAs that are also found at a lower level in normal tissues (which can
cause toxicities in PC patients), thus if CAR T-cells survive for long periods of time in
patients they increase the risk of developing autoimmunity in the future [127]. Furthermore,
activated CAR T-cells containing co-stimulatory domains like CD27, CD28 or 4-1BB
release a variety of inflammatory cytokines like IL-2, IL-6, and IFNγ after encountering
tumor cells which induce macrophages to release more inflammatory cytokines thus
establishing a positive cytokine-based feedback loop to enhance T-cell activity causing
cytokine release syndrome (CRS), which could be fatal for patients [128, 129].
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Development of short-lived CAR T-cells or combination treatment with an IL-6 receptor
inhibitor like tocilizumab could be effective in reversing the effects of CRS without affecting
the activity of CAR T-cells [128, 130].
Human PC malignancy is complex because of its TME architecture and cytokine
milieu that is inefficiently recapitulated in KPC or xenograft mouse models. Secondly, both
tumor cells as well as normal cells express common antigens (though usually at a lower
level than normal cells), and therefore cancer vaccines can potentially cause toxicities in
the patients.

Thirdly, peptide-based cancer vaccines do not capture all unique

immunogenic epitopes present on original tumor antigens. Pancreas-specific transgene
expressing spontaneous PC mouse models, and either protein fragments or intact proteins
as immunogens could address the limitations faced in this field, thereby increasing the
cancer vaccine efficacy. Additionally, selection of PC patient based on both tumor stage
and tumor infiltrating lymphocytes (TILs) like CD8+ and PD-1+ T-cells could further
increase the response to cancer vaccines [131].

6.3 Overcoming Immunosuppression in PC Microenvironment
Nanoparticles are capable of encapsulating multiple proteins, ligands, nucleic
acids and other materials, thus increasing the epitope repertoire. Nanoparticles can also
incorporate immune-stimulatory adjuvants (such as TLR agonists) or chemotherapeutic
drugs to enhance the overall immunogenicity, stability, delivery and/or direct cytotoxicity
of the vaccine, therefore overcoming the limitations of current cancer immunotherapies
[132]. For example, mice immunized with Doxorubicin-CpG-PLGA microparticles showed
a reduced tumor burden at lower drug concentrations compared to mice that received
doses of the soluble drug. When combined with an anti-CTLA-4 antibody, the treatment
successfully reduced aggressive tumor burden at both the injected and distant tumor sites
in tumor-bearing mice [133]. This co-encapsulation of multiple therapeutics and immune
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stimulatory molecules may provide dose-sparing capabilities, reducing the cost and
toxicity of cancer therapeutics [134].
Encapsulation into biodegradable nanoparticles protects the payload until release
[135, 136]. In addition, tuning the polymer chemistry enables sustained and controlled
release of encapsulated payloads [137] and immunomodulatory capabilities [138].
Particularly, it has been demonstrated that varying chemistries of polyanhydride
nanoparticles were efficiently internalized by APCs, leading to the upregulation of MHC I,
major histocompatibility complex II (MHC II) and costimulatory molecules, as well as
inducing the secretion of cytokines [139-141]. In addition, amphiphilic nanoparticles
promoted the production of long-lived, high avidity antibody [142] with suboptimal doses
of antigen [143], suggesting the development of long-lived plasma cells. Polyanhydride
nanoparticles loaded with OVA-induced memory CD8+ T-cells that were recruited and
responded to subsequent challenges with OVA-secreting tumor cells [144]. Finally, many
nanoparticles can be functionalized with ligands or antibodies that may increase selectivity
and reduce the side effects of chemotherapeutics on healthy tissues [145]. Targeting
moieties are often attached to the nanoparticle surface via a polyethylene glycol (PEG)
linker [145]. This method of PEGylation allows for flexibility of the targeting moiety and
may enhance interactions with cancer cell receptors [145, 146]. For example, PLGA
nanoparticles covalently modified with folate via PEG demonstrated an increased
association and uptake with cancer cells in vivo [147].
The limited success of immunotherapeutic studies performed in PC provides a
generous room for improvement. Tailoring immunotherapy to PC patients by identifying
unique tumor-specific antigens through genetic screening and expression studies [49,
148]and combining it with continuous collection and screening of tumor samples in clinical
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trials to understand immunotherapy resistance, will further improve the response rates
and survival benefits of PC immunotherapy.
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Table I: Tumor associated antigens targeted for PC immunotherapy.

Tumor
Associated
Antigen
(Cancer
Antigen)

Mucins
MUC1
MUC4
MUC5AC

Expression
Normal
Pancreas

MUC4 and
MUC5AC are
undetectable,
while MUC1 is
expressed at
low levels.

Pancreatic
Cancer

Aberrantly
overexpressed and
glycosylated in PC
patients

Description

Mucins are glycoproteins that
are differentially overexpressed
in PC but are not expressed in
the normal pancreatic
epithelium (except for MUC1
which is expressed at low
level). These mucins (e.g.,
MUC1, MUC4, and MUC5AC)
are involved in PC
pathogenesis, provide
chemoresistance and enhance
proliferation and survival of PC
cells. Their overexpression has
been correlated with poor
prognosis in patients.
[Ref. No. 54,64,69-70]

Telomerase

Absent

Expressed in 8090% of PC patients

Telomerase is a
ribonucleoprotein enzyme that
catalyzes the synthesis of
telomeric DNA. It is involved in
the formation and protection of
the telomere, which prevents
cells from undergoing
senescence. Telomerase
activity has been detected in
pancreatic juice samples of PC
patients. hTERT expression
and telomerase activity are
predictors of poor outcome in
pancreatic cancer.
[Ref. no. 55, 71-72]

Carcinoembr
yonic
antigen
(CEA)

Absent

Expressed in 77%
of PC patients and
detected in patient
serum.

Carcinoembryonic antigen
(CEA), a glycosylated protein of
MW 180 kDa, is related to
tumor burden of PC due to its
close association with cancer
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cell adhesion, metabolism, and
proliferation. In clinical practice,
CEA is often used to predict the
outcomes of patients with
resectable PC.
[Ref. no. 60,73]

Mutated Kras (G12D)

Absent

Expressed in 89.894.9% of PC
patients

K-ras is mutated in PC cells
and inactivation of the
oncogenic mutant K-ras
enhances MHC I presentation.
K-RAS belongs to the
superfamily of small G proteins
and plays crucial roles in signal
transduction in cells. KRAS mutations in PC transform
and alter the biological behavior
in PC cells including
metabolism reprogramming,
thus playing a crucial role in PC
pathogenesis.
[Ref. no. 77-80]

Vascular
endothelial
growth
factor
(VEGF)

Absent

Expressed in 7793% of PC
patients

VEGF, primarily VEGF-A and
its receptors (VEGFR1 &
VEGFR2), are primarily
involved in the angiogenesis
process in PC cancer.
Increased vascularization of
pancreatic tumors promotes
their growth and metastasis by
providing nutritional flow.
Neovascularization also
facilitates infiltration of protumor immune cells (e.g.,
MDSCs).
[Ref. no. 82-83]

Mesothelin

Absent

Expressed in
~86% of PC
patients

Mesothelin (MSLN) is a
glycoprotein overexpressed in
various epithelial cancers like
mesothelioma and pancreatic,
ovarian, and lung cancers.
MSLN is synthesized as a 71
kDa precursor protein, which is
processed to a 30 kDa
megakaryocyte-potentiating
factor and a 40 kDa MSLN
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protein. It is attached to the
plasma membrane by a
glycosylphosphatidylinositol
anchor and is involved in cell
adhesion. MSLN serves as a
marker of neoplastic
transformation of pancreatic
epithelial cells.
[Ref. no. 86-87]
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Table II: Clinical trials testing antibody-based immunotherapies for pancreatic
cancer.

Clinica
l
Antigen &
Drug

CD40 (CP870,893) 0.2
mg/kg

Trials

Median
progressi
on-free
survival
(months)

Objective
response
rate (%)

22

Completed

7.4
(5.5 to 1
2.8)

5.6
(4.0 to 7.
4)

7.7
(0.2 to 36.
0)

Phase

I

.gov
Identifi
er
NCT00
711191

Status

Median
overall
survival
(months)

No. of
Patien
ts

[Ref.
No. 35]

CD40 (CP870,893) +
Gemcitabine

NCT01
456585
*

I

10

Completed

NRb

NR

NR

PD-1 (CT011) alone or
in
combination
with
Gemcitabine

NCT013
13416*

II

29

Suspended

NR

NR

NR

NCT02
362048
*

II

73

Active

NR

NR

NR

NCT02
009449
*

I

350

Active

NR

NR

NR

NCT00
112580

II

27

Completed

NR

NR

1 patient
had PRc

30

Completed

5.7
(4.3 to 1
4.7)

NR

NR

PD-L1
(pembrolizum
ab)
PD-L1
(pembrolizum
ab)
CTLA-4
(ipilimumab)
CTLA-4
(ipilimumab)
+ Pancreatic
Cancer
Vaccine

NCT00
836407
*

I

* Data obtained from https://clinicaltrials.gov/
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HER1
(Cetuximab)
+ Irinotecan +
Docetaxel

NCT00
042939
*

II

87

Compl
eted

5.3
(4.5 to 9.
4)

4.5
(2.7 to 5.
6)

0.07
(0.024 to
0.198)

HER1
(Cetuximab)
+
Gemcitabine
+
Radiotherapy

NCT00
225784
*8

II

37

Compl
eted

17.3
(2 to N/A
)

9.1
(2 to N/A)

10 out of
37 had PR

HER1
(Cetuximab)
+ Ixabepilon
e

NCT00
38314*

II

54

Compl
eted

7.6
(5.5 to 1
2.2)

3.9
(2.6 to 4.
4)

4 patients
had PR

HER1
(Cetuximab)
+ Irinotecan +
Oxaliplatin

NCT00
871169
*

II

58

Compl
eted

NR

NR

6.9
(1.91 to 1
6.7)

HER1
(Cetuximab)
+
Gemcitabine
+ VEGF
(Bevacizuma
b)

NCT00
326911
*

II

30

Termi
nated

5.41
(3.84 to
6.74)

3.55
(2.00 to 5
.59)

4 patients
had either
PR or CRd

HER1
(Cetuximab)
+
Gemcitabine
+ VEGF
(Bevacizuma
b)

NCT00
091026
*

II

71

Compl
eted

7.9
(5.5 to 9.
5)

5.0
(3.7 to 5.
5)

21
(12 to 32)

HER1
(Cetuximab)
+
Gemcitabine
+ Oxaliplatin

NCT00
338039
*

II

69

Compl
eted

19.2
(14.2 to
24.2)

NR

NR

32

HER1
(Cetuximab)
+
Gemcitabine
+
Capecitabine
+ Radiation

NCT00
305877
*

II

65

Compl
eted

0.38
(0.26 to
0.50)

0.17
(0.08 to 0
.26)

0.30
(0.19 to 0.
42)

HER2
(Trastuzumab
) + Interleukin
12

NCT00
004074
*

I

15

Compl
eted

NR

NR

NR

1.8

44

Compl
eted

4.6

I & II

(2.7-6.6)

(1.7-2.0)

HER2
(Trastuzumab
) + HER1
(Cetuximab)

NCT00
923299
[Ref.
No. 51]

NR

Mesothelin
(SS1(dsFv)PE38
immunotoxin)

NCT00
006981
*

I

NR

Compl
eted

NR

NR

NR

VEGF
(Bevacizuma
b) +
Gemcitabine
+ accelerated
Radiation
Therapy

NCT00
557492
*

II

43

Ongoi
ng

19.7
(16.5 to
28.2)

12.9
(7.0 to 18
.7)

2.3
(0.1 to 12)

VEGF
(Bevacizuma
b) +
Octreotide
Acetate +
Everolimus

NCT01
229943
*

II

75

Ongoi
ng

36.7
(31.8 to
N/A)

16.7
(12.6 to 1
9.7)

31

* Data obtained from https://clinicaltrials.gov/
NR (not reported).
PR (partial response).
d
CR (complete response).
b

c
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Table III: Clinical trials testing T cell-mediated immunotherapies for pancreatic
cancer.

Antigen & Drug

ClinicalTrials.g
ov Identifier

Phase

No. of
Patients

Status

Anti-CEA CAR-T cells

NCT02416466*

I

8

Ongoing

Autologous T cells
transfected with
chimeric antimesothelin
immunoreceptor SS1

NCT01897415*

I

16

Ongoing

CART-meso-19 T cells
+ Cyclophosphamide

NCT02465983*

I

12

Ongoing

GI-4000 Vaccine +
Activated T Cells

NCT00837135*

I

NRb

Withdrawn

MFE23 scFvexpressing autologous
anti-CEA MFEz T
lymphocytes

NCT01212887*

I

14

Terminated
due to
safety
concerns
and lack of
efficacy

Autologous Natural
Killer / Natural Killer T
Cell Immunotherapy

NCT00909558*

I

24

Suspended

Prostate Stem Cell
Antigen (PSCA)
Specific CAR T Cells
(BPX-601) +
Rimiducid

NCT02744287*

I

30

Recruiting

* Data obtained from https://clinicaltrials.gov/

b

NR (not reported).
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Table IV: Clinical trials testing cancer vaccines for pancreatic cancer.

Antigen & Drug

ClinicalTrials.
gov Identifier

Phase

No. of
Patients

Status

MUC1 Vaccine (Cvac
vaccine)

NCT02310971*

II

0

Withdrawn

Falimarev (MUC1
PANVAC-F vaccine) +
Inalimarev (MUC1
PANVAC-V vaccine) +
Sargramostim (GM-CSF
vaccine)

NCT00669734*

I

18

Ongoing

Telomerase vaccine
(GV1001) + gemcitabine
+ Sargramostim +
tadalafil + Radiation
Therapy

NCT01342224*

I

11

Active

Telomerase vaccine
(GV1001) +
Sargramostim +
capecitabine +
gemcitabine

NCT00425360*

III

1110

Completed

CEA vaccine (ALVAC +
vaccinia) + aldesleukin
(IL-2) + Sargramostim

NCT00003125*

II

24

Completed

CEA vaccine (AVX701)

NCT00529984*

I & II

28

Completed

Recombinant fowlpoxCEA(6D)/TRICOM vacci
ne + GM-CSF vaccine +
Sargramostim

NCT00028496*

I

48

Completed

Recombinant fowlpoxCEA(6D)/TRICOM vacci

NCT00128622*

I

24

Completed

35

ne + denileukin diftitox +
therapeutic autologous
dendritic cells
CEA vaccine (TRICOMCEA(6D))

NCT00027534*

I

14

Completed

CEA RNA-pulsed DC
cancer vaccine

NCT00004604*

I

24

Completed

CEA vaccine
(carcinoembryonic
antigen peptide 1-6D) +
incomplete Freund's
adjuvant +
sargramostim

NCT00012246*

II

7

Terminated

K-ras vaccine (TG01) +
GM-CSF + Gemcitabine

NCT02261714*

I & II

32

Active

II

11

Completed

Aldesleukin + ras
peptide cancer vaccine
+ sargramostim +
DetoxPC

NCT00019331*

HLA-A*02:01-restricted
VEGFR1-derived
peptide vaccination

NCT00683085*

I & II

2

Terminated

VEGFR-2
DNA vaccine VXM01

NCT01486329*

I

72

Completed

II

303

Completed

II

93

Ongoing

Mesothelin vaccine
(CRS-207) + GVAX
vaccine + gemcitabine +
capecitabine + 5-FU +
irinotecan or erlotinib +
cyclophosphamide
GVAX Pancreas
+ Mesothelin vaccine

NCT02004262
[Ref no. 87, 88]

NCT01417000

36

[Ref. no. 88]

(CRS-207) +
Cyclophosphamide
Mesothelin vaccine
(CRS-207)

NCT00585845*

I

17

Terminated

Cancer stem
cell vaccine

NCT02074046*

I & II

40

Completed

* Data obtained from https://clinicaltrials.gov/
b

NR (not reported).
(partial response).
d CR (complete response).
c PR
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Figure 1: Pancreatic cancer cells establish an immunosuppressive TME.
Cancer cells secrete various anti-inflammatory cytokines like IL-10, TGF-β, IL-23,
along with angiogenic chemokines (e.g., CXCL1-3, CXCL5, CXCL12, CCL2, and VEGFA), which generate an immunosuppressive tumor microenvironment (TME) and facilitate
cancer initiation, progression and metastasis. Upregulation of the expression of these
cytokines shifts the balance in TME, which facilitates the evasion from immune
surveillance during PC progression [6, 8, 20, 28]. The PC immunosuppressive
microenvironment also includes crosstalk between cancer cells and various myeloid and
lymphoid subsets. Tumor-associated macrophages (TAMs) and myeloid-derived
suppressor cells (MDSCs) express immuno-inhibitory ligands and reactive oxygen
species that inhibit infiltration and activation of T and NK cells [3, 11-13]. MDSCs and
cancer cells also secrete VEGFs that promote angiogenesis, which aids in the metastasis
of the cancer cells [17]. PC tumor cells and pancreatic stellate cells (desmoplasia) secrete
inhibitory cytokines and chemokines, and express inhibitory surface ligands such as
programmed death ligand-1 (PD-L1) and galectin-1 (Gal-1) that lead to inactivation and
apoptosis of cytotoxic (CD8+) and helper (CD4+) T-cells by programmed death receptor1(PD-1) or Gal-1 binding receptor respectively [16, 18, 21, 22]. Treg cells suppress the
functions of activated T-cells and NK cells in the TME [13, 125]. In addition, the rigid
architecture of pancreatic tumor bed provides a physical barrier to T-cells infiltration
thereby excluding them to the edge/boundary of the tumor and thus rendering the
pancreatic tumor as an immunologically ‘cold’ tumor [28-31]. All these cells are involved
in the maintenance of the immunosuppressive TME, and cancer progression.
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Figure 2: Schematic representation of engineering of CAR-T cells.
CAR T-cells are genetically engineered T-cells expressing tumor antigen-specific
chimeric TCR [149, 150]. The modified receptor is a chimera of a signaling domain of the
TCR complex and an antigen-recognizing domain, such as a single chain fragment (scFv)
of an antibody [151, 152]. CAR T-cells are not dependent on antigen presentation by MHC
molecules expressed on APCs for antigen-specific activation. Adoptive cell transfer of
CAR T-cells involves the isolation, stimulation, expansion, transduction, and ultimately reinfusion of human T lymphocytes [153, 154]. First-generation TCRs included only the
intracellular domain of the CD3ζ chain but did not show any significant in vivo efficacy in
transgenic mouse model studies [155]. Second-generation CARs introduced additional
co-stimulatory domains such as CD28, which significantly augmented CAR signaling, and
improved cytokine production and T-cell proliferation, as well as differentiation, and
survival [156, 157]. Third-generation CARs contain multiple co-stimulatory domains such
as 4-1BB (CD137), and whether they have a clinical benefit over second-generation CAR
T-cells is still under investigation [152, 158, 159].
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CHAPTER 1B: MUCINS-BASED
VACCINES AND MUC4 IN
PANCREATIC CANCER
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1. Synopsis
Mucins are high-molecular-weight, heavily O-glycosylated glycoproteins that are
differentially overexpressed in pancreatic cancer. Literature surveys has shown the
instrumental role mucins play in the pathobiology of PC disease. Overexpression, aberrant
glycosylation and pathological role proposes mucins as lucrative targets for developing
targeted therapies. Immunotherapy is one of the strategies that specifically target tumorassociated antigens and simultaneously reprograms the patient’s immune system towards
the targeted killing of tumor cells. MUC1 has been one of the well-explored mucins for
developing PC immunotherapies but achieved limited success in PC patients. MUC4 is
one of the differentially overexpressed mucins in PC and unlike MUC1, MUC4 has unique
tumor specificity since it is undetectable in normal pancreas. MUC4 plays a crucial role in
PC disease progression and metastasis. Further MUC4’s expression has been
demonstrated to be regulated by cytokines such as IFNγ and tumor growth factor beta
(TGFβ), suggesting a possible interrelationship between immune tumor microenvironment
and PC disease aggressiveness. Previous studies have provided evidence that makes a
strong case to evaluate MUC4 as an immunotherapeutic candidate, but to date only limited
studies have been made. Therefore, in this section we have reviewed existing literature
and summarized their findings to make a case for investigating MUC4 as a potential
candidate for PC immunotherapy.
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2. Mucins: A Target for Pancreatic Cancer Immunotherapy
PC cells undergo a cellular and genetic transformation that contributes to the
expression of proteins that are mostly absent in de novo pancreas cells. One of the
families of proteins that is aberrantly overexpressed in PC tumor cells and has been
reported to play a crucial role in the pathogenesis of the disease is mucins. MUCs are high
molecular weight glycoproteins with O-glycosylated variable number tandem repeat
(VNTR) region and consists of 21 family members. Fourteen MUC proteins out of 21 mucin
family members fall under the category of classical mucins, which is characterized by high
molecular weight O-glycoprotein, secreted in the mucus layer, presence of VNTR
sequence, predicted peptide domain containing high percentage of serine and threonine
residues, and lastly a complex mRNA expression of these mucins [1]. MUC glycoproteins
are classified according to their structure and function into two categories:
transmembrane/membrane-bound mucins comprising of MUC1, MUC3A, MUC3B, MUC4,
MUC12 and MUC17; and secretory/gel-forming mucins consisting of MUC6, MUC2,
MUC5AC and MUC5B [2].
Transmembrane mucins like MUC1, MUC4 and MUC16 are differentially
overexpressed by PC cancer cells and their expression gradually increases with the
progression of the disease [3-9]. MUC1 and MUC4 interact with various receptors such as
receptor tyrosine kinases (RTKs) including epidermal growth factor receptor (EGFR),
ERBB2 & ERBB3, and fibroblast growth factor receptor (FGFR), that promotes
proliferation, invasion, metastasis and resistance to therapeutic anti-RTK (Receptor
Tyrosine Kinase) antibodies [10-14]. MUCs expressed on the PC cancer cell surface due
to their large structure interact with the TME that induce immune evasion and oncogenic
signaling-mediated angiogenesis and metastasis [2]. Studies have demonstrated that
MUCs like MUC1 on PC cells interact with TAMs through sialoadhesin [15]. Interaction
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between M2 macrophages with PC cells via CA125 (carbohydrate epitope located on
MUC16) differentiates these macrophages to immunosuppressive phenotype and induces
secretion of IL10 cytokine [16]. In addition to MUC’s crucial role in pathogenesis and
immunosuppression of PC, they undergo aberrant glycosylation due to the altered
expression and localization of glycosyltransferases [17]. Thus, these aspects make MUCs
an important therapeutic target for PC immunotherapy strategies.

2.1 Mucin-based Cancer Vaccines for PC
Due to their contributions in PC pathogenesis, MUCs have been targeted by
immunotherapy strategies like cancer vaccines to efficaciously treat PC patients. We have
previously discussed MUC vaccines studied and tested in both pre-clinical and clinical
trials for PC immunotherapy in our previous chapter [18]. In addition, a recent pre-clinical
study with MUC1-based DNA vaccine (pVAX1-MUC1-VNTRn DNA vaccine) showed that
MUC1-VNTR6- and MUC1-VNTR9- transfected DCs were able to activate IFN-γ producing
CTLs, increase the cytotoxicity of CTLs and suppress Panc02-MUC1 PC tumor cell’s
growth in tumor-bearing mice [19]. Mice immunized with MUC1-tandem repeat B-cell
peptide conjugated with Ttox (MUC1-Ttox vaccine) produced high titers of anti MUC1 IgG
antibodies. These IgG MUC1 antibodies could specifically differentiate between human
normal and PC tumor cells [20]. A clinical trial (NCT03114631) with DCs pulsed

with MUC1/WT-1 peptides is currently under investigation for treating both resectable
and unresectable PC patients.

2.2 Limitations of Mucin Vaccines for PC Immunotherapy
Efficacious MUC cancer vaccines have been a challenge to develop because tumor
antigens like MUC1 are also expressed by normal cells (self-antigens) causing the
immune

system

to

develop

self-tolerance

against

them,

which

leads

to

61
hyporesponsiveness of APCs upon exposure to MUC1 cancer vaccines. Efficient
activation of DCs is instrumental to activate cellular and humoral responses in an antigenspecific phenotype. In a very detailed study done in MUC1.Tg mice, it was observed that
MUC1p cancer vaccine couldn’t successfully activate APCs post vaccination in MUC1
expressing MUC1.Tg mice and was unable to restrict the growth of both transplanted and
spontaneous PC tumors [21]. Whereas in WT mice, MUC1p cancer vaccination activated
DCs and induced significant expression of surface markers like MHC-II, CD80, CD86 and
CD40. Upon further investigation they discovered that MUC1.Tg immunized mice had a
higher percentage of Fox3+ Tregs cells and these Tregs inhibited the expression of pancreatic
enzymes such as trypsin and CBP1 transcript in DCs recovered from spleens of MUC1.Tg
mice. Specific depletion of Tregs by anti-CD25 treatment or blocking of IL-10 by anti-IL10R
antibody prior to MUC1p cancer vaccination rescued the expression of these enzymes in
DCs to the similar levels of DCs isolated from WT mice [21]. This study suggests the
necessity of discovering TAAs that are distinct from their counterparts being expressed on
normal cells to prevent the formation of self-tolerance against them. A strategy to
recognize MUCs against which self-tolerance is likely compromised in naïve PC patients
who haven’t received any treatments or surgery, could enable identifying the immunogenic
MUC candidate that will probably overcome the hyporesponsiveness of APCs and
generate corresponding anti-tumor responses.
Another limitation of MUC vaccines is the number of available epitopes to activate
APCs. Peptides from VNTR region of MUC proteins have been utilized to develop cancer
vaccines like peptide-toxin vaccines [20] or DC vaccines [19]. But these vaccines have
achieved only limited success in clinical trials. Peptide-based vaccines have certain
limitations such as peptides are mostly designed to have an MHC-I restriction that leads
to the presentation of individual peptides on only certain HLA types. In addition, if selected
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peptides have low affinity for MHC, they may be poorly immunogenic and induce weak or
transient immune responses by APCs upon exposure [22]. As previously discussed in our
review [18], protein provides an array of epitopes having multiple immunogenicities and
thus could be presented by different MHC-I HLA types, potentially leading to the
generation of strong immune responses. Expression, isolation and purification of
transmembrane MUC glycoproteins come with its challenges. Due to the high molecular
weight of MUCs, their purification and maintenance of their native antigenicity have not
been feasible to date.

3. MUC4 as Tumor-Associated Antigen for PC
3.1 MUC4 in Pancreatic Cancer
In contrast to MUC1, MUC4 expression in normal organs is mostly restricted and is
undetectable in normal pancreas and inflammatory diseases of the pancreas [23, 24] thus
providing a better tumor specificity for targeting purposes. MUC4 is one of the most
differentially overexpressed multi-domain transmembrane glycoprotein in PC [2, 7, 23, 25].
MUC4 protein carries a high percentage of allelic polymorphism in the VNTR domain that
is rich in serine, threonine, and proline residues and it extensively undergoes mucin-type
O-linked glycosylation [2, 23, 26] thus contributing to the high molecular weight of the
apoprotein. MUC4 has a putative cleavage site comprising of Glycine-Aspartate-ProlineHistidine (GDPH) that can undergo autocatalysis and generate two subunits: MUC4α
upstream of GDPH cleavage site and MUC4β downstream of the site [26-28]. MUC4α
subunit is the large N-terminal domain that is composed of VNTR domain, nidogen-like
domain (NIDO), and adhesion-associated domain in MUC4 and other proteins (AMOP).
MUC4β on the other hand is a smaller subunit composed of von Willebrand factor type D
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domain (vWD), three epidermal growth factor (EGF)-like domains, a transmembrane
domain and a short cytoplasmic tail [23].
MUC4 has been demonstrated to play a fundamental role in the pathobiology of PC.
Over the years studies have shown that MUC4’s interaction with EGFR family members,
HER2 and HER3 is mediated by the 3 EGF-like domains present in the MUC4β subunit
[29-31]. These interactions subsequently activate an intracellular cascade of signaling
events

including

mitogen-activated

protein

kinases

(MAPK),

c-Jun

N-terminal

kinases (JNK), and signal transducer and activator of transcription 1 (STAT-1) that
promote cell proliferation, migration and metastasis [12, 29-32]. The NIDO domain on
MUC4 interacts with fibulin-2 that competitively disrupts its interaction with extracellular
matrix (ECM) proteins present in the basement membrane, thus abrogating normal ECM
protein-protein interactions [33]. An overall survey of the literature shows that MUC4 can
modulate diverse pathways such as drug resistance [34], epithelial to mesenchymal
transition (EMT) and metastasis [35], tumor cell proliferation and invasion [12], and thus
PC patients with a MUC4 expression on tumors have a worse prognosis [36]. Given the
tumor-promoting nature and PC-specific expression of MUC4, various studies have
focused on utilizing MUC4 as a diagnostic/prognostic marker. MUC4 has emerged as a
useful diagnostic tool for PC in fine needle aspirates (FNAs) [37, 38]. Also studies with
patient serum samples for MUC4 serving as biomarkers have been investigated [39, 40].
In summary, MUC4 has been undisputedly established as a PC tumor-specific molecule
that plays an instrumental role in progression and metastasis of PC disease, as well as
serves as a useful diagnostic marker.

3.2 Immune Regulation of MUC4 in Pancreatic Cancer
Multiple signaling pathways regulate MUC4 expression in PC through the binding of
different transcription factors at the MUC4 promoter site [41, 42]. Previous studies have
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shown cytokine-mediated expression of MUC4 in PC cells. IFNγ and retinoic acid (RA)
synergistically upregulates the expression of MUC4 in PC cells through the dual activation
of STAT-1 and transforming growth factor beta-2 (TGFβ) pathways [43, 44]. TGFβ can
upregulate MUC4 expression either by cooperative activation of Smad3 and Smad4
signaling pathways, or by activating MAPK, phosphatidylinositide 3-kinases (PI3K) and
protein kinase A (PKA) signaling pathways [45]. Further, in other cancers such as gastric
and colon cancer cell lines, it has been observed that interleukin (IL)-4, IL9, IL6, & IL24
could upregulate MUC4 expression by activating JAK/STAT pathway [46, 47] or in a
STAT-3 dependent manner [48, 49]. PC has an elaborate TME composed of multiple
immune cells such as TAMs, MDSCs, M2 macrophages etc. that secrete Th2 cytokines
such as IL4, IL9 and IL24 (an IL-10 cytokine family member) to establish and maintain
immunosuppression [18]. In addition, aberrant glycosylation of MUC4 appears to induce
MUC4-specific immune responses such as generation of both Th1 and Th2 cytokines in
MUC4-expressing pancreatic tumors [44]. Cumulatively these studies demonstrate that
immune cells in TME can regulate the expression of MUC4 on PC cells by secretion of
cytokines, which reveals an unexplored relationship between MUC4 and PC
immunosuppression.

4. Summary and Conclusion
PC immunotherapy faces some major challenges in the selection of a suitable antigen.
It has to meet three criteria: tumor-specific expression, antigen availability due to sufficient
expression, and high immunogenicity to elicit strong immune responses. Due to its
deregulated overexpression in PC and functional role in pathogenesis, MUC4 has
emerged as a promising diagnostic and therapeutic candidate. MUC4’s central role in
eliciting tumor proliferation, invasiveness, drug-resistance and metastasis, has led to
considerable interest in targeting MUC4 to avail therapeutic benefits. Further, due to
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aberrant glycosylation [50] and cleavage [26-28], MUC4 expressed on PC tumor cells will
be distinct from the expression on normal tissues. Circulating autoantibodies to MUC4 has
been detected in colorectal patients [51] and preliminary study with MUC4 peptide-induced
DNA vaccine showed that MUC4 DC vaccine could efficiently present the antigen and
elicit potent MUC4-specific CTL response [52].
Further, the structural complexity and various glycoforms of MUC4 adds a challenge
in designing strategies for immunotherapy. Previous studies have been focused on
peptides located in the VNTR region. Since MUC4 could putatively get cleaved at the
GDPH site into alpha and beta subunits, thus there is a possibility of MUC4α (containing
VNTR domain) to be not attached to the cell surface of tumor cells because MUC4
fragments have been discovered in secretions [53, 54].
In conclusion, MUC4 is a cancer-specific tumor-promoting glycoprotein that could
serve as an effective antigen to develop vaccines against PC. However, investigations
exploring MUC4 as a candidate for immunotherapy are in infancy. It requires multiple
optimizations like identifying optimal biodegradable adjuvant delivery systems,
identification of helper epitopes and developing platforms with good adjuvant properties
that conserve the antigenicity of the epitopes. Thus, further studies are necessary to
establish MUC4 as a suitable target for PC immunotherapy.
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HYPOTHESIS AND OBJECTIVES
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1.

Background and Rationale
PC is the third leading cause of cancer-related death in the U.S. claiming 45,000

lives every year because of its poor prognosis and resistance to conventional therapies
[1]. Much like other solid tumors, PC evades immune surveillance by manipulating immune
cells to establish an immunosuppressive TME. Immunotherapy has emerged as an
alternative approach for PC immunotherapy. It reprograms the patient’s immune system
to selectively target and kill cancer cells thus reducing the non-specific side-effects. PC
immunotherapy faces multiple challenges such as: i) identification of tumor-associated
antigen that could be targeted; ii) preservation of TAA antigenicity and its sustained
delivery; iii) generation of

robust anti-tumor responses; and iv)

overcoming

immunosuppression on effector immune cells in PC tumor microenvironment.
PC harbor limited genetic alterations which render it as an immunologically ‘cold’
tumor. Overexpression and altered glycosylation of mucins in tumor cells can trigger
humoral and cellular immune responses. Among various mucins, MUC4, heterodimeric
transmembrane mucin is aberrantly overexpressed in PC but is undetectable in normal
pancreas and is associated with poor prognosis in PC patients [2]. In PC, MUC4 is
aberrantly glycosylated, and thus could serve as a potential source of neoantigenic
epitopes, which could be exploited for cancer immunotherapy. Additionally, due to the
transmembrane nature of MUC4 only a very limited amount is released into the blood, and
that makes MUC4 a very strong candidate for vaccine [3-6]. A survey of literature has
shown that mucins like MUC1 have been targeted by immunotherapy approaches for PC
treatment but have not fared well in clinical trials. Further detection of circulating serum
autoantibodies to MUC4 has shown its potential to be immunogenic in colorectal cancer
patients [7]. However, MUC4 immunogenicity in PC patients has yet not been studied.
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These summarized findings suggest that MUC4 has potential to be a candidate for PC
immunotherapy.
Polyanhydride nanoparticles represent an ideal vaccine adjuvant/delivery platform.
Polyanhydride nanoparticles have been demonstrated to provide sustained release and
enhanced stability of encapsulated antigens (peptides, proteins etc.) [8]. The ratio of
polyanhydride nanoparticle’s formulation provides an immune modulation property that
could be utilized to tune the immune responses to either Th1 or Th2 phenotype [9, 10]. In
addition, their adjuvant properties enhance antigen internalization by antigen-presenting
cells and stimulate both antibody- and cell-mediated immunity [11-13]. Due to their
pathogen-mimicking, immune-modulation and biodegradable nature, the polyanhydride
nanoparticles platform could be utilized to develop vaccines for PC immunotherapy.

2.

Hypothesis
Based on previous studies demonstrating the tumor-specific overexpression of

MUC4 in PC and suitable qualities of polyanhydride nanoparticles to serve as a vaccine
delivery platform, we hypothesized that i) MUC4 is immunogenic in PC patients, and ii)
delivery of encapsulated MUC4 in unique amphiphilic polyanhydride nanovaccine will elicit
robust immune responses in an antigen-specific manner.

3.

Objectives

Aim 1: To determine whether tolerance will be broken against MUC4 in pancreatic cancer
patients and elucidating it as a suitable target it for immunotherapy studies.
Aim 2: To evaluate whether MUC4 nanovaccine can elicit robust immune responses.
Aim 3: To evaluate whether MUC4 nanovaccine can elicit antigen-specific anti-tumor
responses in PC-subcutaneous tumor-bearing mouse model.
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1. Human Serum Sample Description
Human sera were obtained after written informed consent was acquired from
individuals {the protocol was approved by the UPMC Review Board (IRB number
PRO07030072), and UNMC Review Board (IRB number 209–00)} from the University of
Pittsburgh Medical Center (UPMC) and shipped to UNMC. Patients with benign
pathologies or abnormal imaging of pancreas were categorized as Healthy; PC staging
was determined surgically by pathologists; chronic pancreatitis (CP) was defined based
on standard clinical practices at UPMC. Sera from PC patients were collected close to the
time of the first diagnosis of cancer, prior to surgery and before chemotherapy treatment.
All samples collected at UPMC were shipped by overnight mail to the UNMC. After
receiving the samples, they were stored following clotting of sera for 30 min, aliquoted and
immediately frozen at -70°C within 60 min of collection. The sample set was comprised of
21 CP patients, 27 Healthy, and 31 PC patients, which could be divided among 16 earlystage patients (Stage I–II) and 15 late-stage patients (Stage III–IV) who were recruited at
UPMC. To evaluate the presence of autoantibodies against MUC4 peptides, randomized
patient sera was selected to make a cohort of 10 Healthy, 10 CP patients and 22 PC
patients. Details on the groups of patients are provided in the supplementary section, and
patient demographic data are described in Supplementary Table 1 &2.

2. Prediction of MUC4 Immunogenic Peptides by Bioinformatics
MUC4 immunogenic peptides were predicted by multiple software: T-cell epitopes
for human MHC-I (most common: HLA-A*-02:01) were predicted and scored by Immune
Epitope Database and Analysis Resource (IEDB) [24-31] and TepiTool [32], and combined
human HLA isoforms scores were predicted by NetCTL-1.0 [33] online prediction tools.
Human MUC4 peptides that could be loaded on C57BL/6 mouse MHC-I & MHC-II
complexes were predicted and scored by IEDB online prediction tool; and linear B cell
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epitopes were predicted and scored by IEDB and BCPred [34] online prediction tools.
Lowest percentile rank scoring peptides were selected to be synthesized for our study.
For our study, we selected the amino acid sequence derived from the MUC4 sequence
isolated and characterized at www.uniprot.org (UniProtKB/Swiss-Prot: Q99102.4) [20, 22,
35, 36].

3. MUC4 Peptide and MUC4β Purification
Predicted MUC4 9-mer-amino-acid peptides, MUC4 VNTR peptide (TR) and
pancreatic differentiation 2 (PD2) peptide used in this study were locally synthesized and
purified at UNMC. Seven peptides from the randomized regions of MUC4α (excluding the
TR region) and four peptides from the MUC4β region (upstream of the transmembrane
domain) were used to detect autoantibodies in PC patients, CP patients and Healthy sera.
Recombinant human MUC4β protein was expressed in E. coli R-2 (DE3) strain
transformed with MUC4β-6-His-Tag expression plasmid and purified by AKTA Ni-NTA
affinity chromatography. Eluted protein fractions were assessed by Coomassie Blue
stained 10% SDS-PAGE gels and by immunoblotting using anti-His tag antibody (Thermo
Fisher, Pierce # 31430), confirming the presence of MUC4β fractions. MUC4β fractions
were concentrated by using Amicon Ultra centrifuge filters and further purified by dialysis
in ultra-purified endotoxin-free water. Purified MUC4β fractions were passed through an
endotoxin removal spin column (Thermo Fisher, Pierce # 88277) and the final endotoxin
level measured by Pierce LAL Chromogenic Endotoxin assay kit (Pierce, # 88282) was
less than <1. The purified recombinant MUC4β protein fraction was quantified by BCA
protein assay kit (Thermo Fisher, Pierce # 23225) for the study.
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4. Encapsulation of MUC4β in Polyanhydride Nanoparticles
The 20:80 CPTEG:CPH polymer was synthesized via melt polycondensation [23].
Next, nanoparticles encapsulating MUC4β were synthesized using a solid-oil-oil double
emulsion technique previously described in [28]. Briefly, purified MUC4β was dialyzed to
nanopure water and lyophilized. Next, 20:80 CPTEG: CPH polymer containing three wt.%
MUC4β was dissolved 20 mg/mL in methylene chloride. The solution was sonicated for
30 s to ensure even distribution of the protein. The nanoparticles were precipitated into
chilled pentane (-10°C; 1:250 methylene chloride: pentane) and collected via vacuum
filtration. Nanoparticle morphology was verified by scanning electron microscopy (FEI
Quanta 250, FEI, Hillsboro, OR) and their size subsequently analyzed with ImageJ
(ImageJ 1.48v, NIH). The release kinetics of MUC4β from 20:80 CPTEG: CPH
nanoparticles were monitored as previously described [22]. Briefly, nanoparticles were
incubated in PBS at 37°C. Periodically, the samples were centrifuged, supernatant
collected, and particles were resuspended in fresh buffer. The amount of protein in the
collected supernatant was quantified using a microBCA assay. At the end of approximately
one month, the buffer was exchanged with 40 mM sodium hydroxide to quickly degrade
the nanoparticles and release any remaining protein. The encapsulation efficiency was
determined by comparing the total amount of protein released to the amount theoretically
encapsulated.

5. Primary Dendritic cells (DCs) Isolation
C57BL/6 mice were kept under SPF conditions at UNMC animal facilities in
accordance with UNMC Institutional Animal Care and Use Committee (IACUC) standards.
Femurs and tibiae of female, 6-8 weeks old female C57BL/6 mice were removed and
purified from the surrounding muscle tissue by rubbing with kleenex tissues. Thereafter
intact bones were disinfected in phosphate buffered saline pH 7.2 (PBS) containing
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penicillin (100 U/mL, Sigma) and streptomycin (100 m/mL, Sigma) solution for 2-5 min.
Then both ends were cut with scissors and the marrow was flushed with PBS using a 1
mL syringe attached to 25 G needle. Homogenous pipetting disintegrated clusters within
the marrow suspension. Cells were centrifuged at 2000 rpm for 2.5 min and the cell pellet
was resuspended in 10 mL of 1X RBC lysis buffer in the dark for 5 min. Ten mL of RPMI
was added to stop the lysis. Cells were centrifuged at 2000 rpm and washed 3 times in 10
mL of RPMI. After the last wash, cells were resuspended homogeneously in a 1 bone:1
mL of media ratio. Resuspended cells were passed through a single cell strainer to remove
clumps. Single cell suspensions were poured in 10 mL RPMI containing 10% FBS,
penicillin (100 U/mL, Sigma) and streptomycin (100 mg/mL, Sigma) media in a 10 cm
tissue culture plate that was kept in an incubator for 3 h. After incubation, we collected all
floating cells and washed the plate with media twice to collect rest of the suspended cells
in a 50 mL falcon tube. The cells were pelleted by centrifugation and the media aspirated.
The cells were resuspended in 10 mL RPMI media and transfered into T75 flasks for our
in vitro studies.

6. DC Maturation and Pulsing
To enhance the DC population, we added 100 ng/µl of rmGM-CSF and 50 ng/µl
rmIL-4 reconstituted and diluted in serum-free RPMI to freshly isolated DC cultures on
Day 0. On Day 3, 5, and 7, we collected the nonadherent cells in 50 ml centrifuge tubes,
pelleted them and resuspended them in a total volume of 10 ml having 75% of fresh media
containing 10% FBS + antibiotics and 100 ng/µl of GM-CSF and 50 ng/µl IL-4 in a fresh
T75 flask. At day 9, immature DCs were counted and seeded in 24 well plate for activation
studies. Polyanhydride nanoparticles were suspended in complete culture medium,
sonicated briefly (30s on ice), and added to the DC cultures at day 9 at a concentration
of 100 μg/mL. DCs were pulsed in the following groups: 3 µg/ml free MUC4β protein
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(MUC4), free MUC4β protein (3 µg/ml) mixed with blank nanoparticles (100 μg/mL)
(MUC4+NP) and MUC4 nanovaccine (100 μg/mL). Unstimulated DCs (US) and DCs
stimulated with LPS (200 ng/mL) were used as negative and positive controls,
respectively. Cultures were incubated for 48 h (37 °C, 5% CO2). Activated dendritic cells
were harvested from 24-well plate and centrifuged at 1000 x g for 5 minutes to collect the
culture medium and the pellet was processed further for flow cytometry studies.
Supernatant was collected for ELISA studies from each treatment groups.

7. Flow Cytometry of Activated DCs
Dendritic cells were resuspended and washed 3 times in FACS buffer {1X PBS (pH
7.2) + 1% Fetal bovine serum (FBS)} to remove any residual culture medium. DCs were
fixed in 4% paraformaldehyde for 15 min at RT and washed by centrifugation with excess
FACs Buffer. After that, the 1X105 DCs were resuspended in100 µl volume of conjugated
antibody cocktail for detection of DC surface markers consisting of CD11c, MHC-I, MHCII, CD40, CD80, CD86, and CD205 was prepared at 1:300 dilution in FACs Buffer.
Corresponding isotype controls were also prepared at 1:300 dilution in FACs buffer. The
washed DCs were suspended in either DC surface markers antibody cocktail or in
isotype-antibody cocktail and incubated for 60 min on ice (40C) in the dark. The labelled
cells were again washed and analyzed using a BD LSR-II Green Flow Cytometer (BD
Biosciences). FlowJo® and BD FACSDIVA software were used to analyze the data.

8. Cytokine Analysis by ELISA
Supernatants were preserved at -800C and thawed on ice for cytokine analysis. IL-6,
IFN-γ and IL-12/IL-23p40 cytokines in supernatants were measured by enzyme-linked
immunosorbent assay (ELISA) kits from BioLegend and the manufacturer’s protocol was
followed for the assay. 96-well ELISA strips were coated with capture antibodies (1:200
dilution) diluted in carbonate-bicarbonate buffer (0.5M, pH 9.6) and incubated overnight
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at 40C. The next day coated strips were washed 4 times with 1X PBST (0.05% Tween 20)
and blocked with 3% bovine serum albumin (BSA) in PBS for 2 hours at 370C. Strips were
then washed 4 times and 100 µl of supernatants were added to coated strips and
incubated for 2 hours at 370C. Plates were washed with PBST for 4 times, followed by
incubation with detection antibody (1:200) for 1 hour at 370C. Secondary antibody was
washed away with 4 PBST washes. Avidin (1:1000) was added to ELISA strips and
incubated for 30 min at RT in dark. Excess Avidin was washed away with 5 PBST
washes, followed by addition of TMB (3,3',5,5'-Tetramethylbenzidine) substrate in the
dark and incubated at RT for color to develop. Absorbance was measured after the
reaction was stopped (~15 mins) with 1N H2SO4 at 450 nm using a SpectraMax® Plus384
microplate reader (Molecular Devices LLC, Sunnyvale, California). For serum cytokines
analysis, serum samples were collected post-animal sacrifice and stored at -800C. Serum
samples were added at 1:10 dilution to capture-antibody coated plates for cytokine
analysis. IL-6, IFN-γ and IL-12/IL-23p40 were measured by ELISA kits from BioLegend
using a similar manufacturer’s protocol.

9. Mice Immunization for Anti-MUC4 Antibodies Generation
Eight weeks C57BL/6 mice were immunized with various formulations of
recombinant MUC4β protein, including protein alone (20 µg/mouse/dose), encapsulated
MUC4β protein (300 µg/mouse/dose), protein plus nanoparticle, and saline control,
constituted in Freund’s adjuvant. First booster dose was given after 2 weeks of primary
immunization. The blood was withdrawn form submandibular vein after 1 week of a single
booster dose. The serum was isolated from the blood after overnight storage at 4°C and
stored at -20 °C for further use.
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10. MUC4 Autoantibody ELISA
To detect circulating MUC4 autoantibodies in sera of the sample set, a novel
modified sandwich ELISA-assay was developed. Briefly each 96-well plate was coated
with five μg/mL of recombinant MUC4β protein or with one μg/mL of MUC4 peptides or
control peptides (PD2 & TR) in carbonate-bicarbonate coating buffer (0.5 M, pH 9.6) and
incubated overnight at 40C. The plate was washed two times with 1X PBST and blocked
with 3% BSA in PBS for 3 hours at 370C. Further, the plate was washed four times and
then a serial dilution (1:16000) of the serum samples were added to MUC4β-coated plate
and a serial dilution of 1:2000 was added to MUC4 peptide-coated plates. ELISA plates
with primary serum dilutions were incubated overnight at 40C. Plates were washed with
PBST for four times, followed by incubation with horseradish-peroxidase (HRP)
conjugated goat anti-human IgM+ IgG+ IgA (H+L) (Jackson ImmunoResearch), or for
isotyping HRP conjugated IgM, IgG (H+L) and IgA (Jackson ImmunoResearch)
respectively for 1 hour at 370C. The excess secondary antibody was washed away with 5
PBST washes and followed by addition of TMB substrate in the dark. Absorbance was
measured after the reaction was stopped (~15mins) by adding 1N H2SO4 at 450 nm using
a SpectraMax® Plus384 microplate reader (Molecular Devices LLC, Sunnyvale,
California).

11. Anti-MUC4β Antibodies Detection in Immunized Mice Serum Using
ELISA
Serum samples were collected post-animal sacrifice and stored at -800C for detection
of anti-MUC4β antibodies using ELISA techniques. To detect anti-MUC4β antibodies, we
used a modified ELISA protocol. A 96-well plate was coated with 5 μg/mL of recombinant
MUC4β protein in carbonate-bicarbonate coating buffer (0.5 M, pH 9.6) and incubated

85
overnight at 40C. Plate was washed 2 times with 1X PBST and blocked with 3% BSA in
PBS for 3 hours at 370C. Further, the plate was washed 4 times and then serial dilutions
of the serum samples were incubated in MUC4β coated plate for 2 hours at 370C. Plates
were washed with PBST for 4 times, followed by incubation with horseradish-peroxidase
(HRP) conjugated goat anti-mouse IgG (total H+L) (Thermo Fisher), IgG1 (Abcam) and
IgG2b (Abcam) for 1 hour at 370C. Excess secondary antibody was washed away with 5
PBST washes and followed by addition of TMB substrate in the dark. Absorbance was
measured after the reaction was stopped (~15 min) with 1N H2SO4 at 450 nm using a
SpectraMax® Plus384 microplate reader (Molecular Devices LLC, Sunnyvale, California).

12. Generation of MUC4-Expressing Murine PC Cell Lines
A MUC4-expressing mouse pancreatic cancer cell line derived from KPC mice
(KPC960) was developed by transfection of KPC960 cell lines with miniMUC4-pSecTagC
plasmid using the Lipofectamine method (Invitrogen) and single colonies were obtained
by zeocin selection as published previously in Moniaux et.al 2007 and confirmed by
immunoblotting with a MUC4 peptide mouse monoclonal antibody (8G7). The miniMUC4
expressing KPC960 cells were kindly developed, validated and gifted by Dr. Shailendra
Gautam for our in vivo and ex vivo studies.

13. Tumor Implantation and Mice Immunization
For in vivo characterization of MUC4 nanovaccine in mice, 8 weeks C57BL/6-FBP
mixed background mice were immunized with different formulations of recombinant
MUC4β protein, including protein alone (MUC4- 35 µg/mouse/dose), free MUC4 protein
mixed with nanoparticles (MUC4+ NP) (35 µg/mouse/dose of MUC4 + 500 µg/mouse/dose
empty nanoparticles), MUC4 nanovaccine (500 µg/mouse/dose), and unimmunized mice
(negative control). First booster dose was given after two weeks of primary immunization.
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Two weeks after first booster, mice were injected with 1x106 cells of mini-Muc4 or Vector
expressing KPC derived mouse pancreatic cell lines(KPC960) into right and left flanks of
mixed background mice (n=5), respectively. Tumor growth was monitored till the tumor
volume reached to 100mm3 volume. Mice were then immunized with second booster dose
but the MUC4 protein dose was reduced to 20 µg/mouse/dose in all treatment groups
except for saline control. Tumors were harvested at 23rd-day post second booster
immunization and preserved in formalin for further use.

14. T-cell Isolation and In Vitro Activation
Naïve T-cells were isolated from 8-10weeks old C57BL/6-FBP mixed background
mice. Mice were sacrificed, and spleens were isolated in RPMI+10%FBS+Pen-Strp
(RPMI) medium in 50 ml Falcon tube on ice. Media was removed by suction inside the
laminar hood and one spleen was added to one of the wells of 6 well plates. Spleens were
teased with a 25G syringe needle and 1 ml pipette tip. Teased-out splenocytes were
transferred to 15 ml falcon tube in RPMI media and was centrifuged for 2-3mins at 2000
rpm. The supernatant was removed and the pellet was resuspended in 10-12ml of 1X
RBC lysis buffer, then the tube was kept for 5 min in the dark. The tube was centrifuged
again for 2-3 min at 2000 rpm and the supernatant was aspirated. The pellet was
resuspended and splenocytes were washed for 3 times with RPMI media. After the last
wash, the pellet was resuspended in 2 ml of RPMI media and counted total cells/ml. We
centrifuged the cell suspension at 2000 rpm for 10 min and removed the supernatant
completely. We resuspended the cell pellet in 40 μL of MACs Buffer (1X PBS pH 7.2, 0.5%
BSA, 2mM EDTA) per 107 cells. We added 10 μL of Pan T cell Biotin-Antibody Cocktail
(MACS Miltenyi Biotech, Inc.) per 107 cells and mixed it well. We incubated the mixture for
5 min in the refrigerator (2-8o C) and then added 30 μL of MACs buffer per 107 cells, and
followed by addition of 40 μL of Anti-Biotin Microbeads per 107 cells. We mixed all the
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components well & incubated for additional 10 min in the refrigerator (2-8o C). We took the
mixture and processed the sample in an autoMACS® Pro Separator (MACS Miltenyi
Biotech, Inc.). Tubes were placed in the following Chill Rack positions: position A =
sample, position B = negative fraction position C = positive fraction. We prepared and
primed the instrument and followed the instructions that were given in the user manual. T
cells were isolated by magnetic separation and we used the ‘Depletes’ program to do the
separation into positive (other splenocytes) and negative (T cells) population.
Naïve T-cells were then cultured and expanded in RPMI on day 0. On day 1,
purified T cells were incubated with phorbol 12-myristate 13-acetate (PMA) (25 ng/mL)
Ionomycin (500 ng/mL, Abcam) for 48 hours at 37°C. On day 3, these T-cells were cocultured in 12-well plate with 48hour-pulsed DCs in the following groups: 3 µg/ml free
MUC4β protein (MUC4), free MUC4β protein (3 µg/ml) mixed with blank nanoparticles
(100 μg/mL) (MUC4+NP) and MUC4 nanovaccine (100 μg/mL). Unstimulated DCs (US)
and DCs stimulated with lipopolysaccharides {LPS} (200 ng/mL) were used as negative
and positive controls, respectively. T-cells were co-cultured for 48 hours with pulsed DCs
and then collected for further analysis. The experiment was done in triplicates.
Since the Pan T cell Isolation kit can purify both naïve and activated T cells, a
similar T-cell isolation protocol was utilized to isolate T-cells from immunized mice and
expanded in vitro by treatment with PMA/Ionomycin (25 ng/mL/500ng/mL, Abcam) for 48
hours at 37°C. On day 3, the expanded T-cells were analyzed by flow cytometry for
phenotyping T-cells and cytokine secretion studies.

15. Cytotoxicity Assay of T-cells
The miniMUC4 KPC960 cells and KPC960 vector control cells (500 cells/well)
were seeded in 96-U bottom plates and cultured overnight in a 370C incubator. The plate
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was centrifuged and the media was removed. Activated T-cells were added from each of
the treatment groups to target cancer cells at 10:1 dilution into their respectively labeled
wells. T-cell mediated cytotoxicity was measured by the CytoTox 96® Non-Radioactive
Cytotoxicity Assay Kit (Promega) and the manufacturer’s protocol was followed for the
assay. The plate was centrifuged at 250 × g for 4 minutes and the plate was incubated at
37°C for 4 hours. At 45 minutes prior to supernatant harvest, Lysis Solution was added to
wells of both cancer cell lines that didn’t have T-cells added to them, which served as our
Target Cell Maximum LDH Release Control. The plate was centrifuged at 250 × g for 4
minutes and 50 μl of the supernatant from each well of the assay plate was transferred to
the corresponding well of a flat-bottom 96-well enzymatic assay plate. Substrate Mix was
reconstituted using Assay Buffer and 50 μl of the reconstituted Substrate Mix was added
to each well of the plate. The plate was incubated at room temperature in the dark for 30
min. Absorbance was measured after the reaction was stopped with 50 μl of the Stop
Solution at 450 nm using a SpectraMax® Plus384 microplate reader (Molecular Devices
LLC, Sunnyvale, California).

16. Flow cytometry of Activated T-cells
T-cells isolated from immunized mice were expanded by PMA + Ionomycin
treatment. Brefeldin A (2 ug/mL) was added to the treated flask and untreated flask and
cells were incubated for 4 hours in a 37oC incubator. T-cells were resuspended and
washed three times in FACS buffer {1X PBS (pH 7.2) + 1% Fetal bovine serum (FBS)} to
remove any residual culture medium. After that, the 1X105 T-cells were resuspended in
100 µl volume of conjugated antibody cocktail for detection of T-cell surface markers
(consisting of Th1 phenotype CD4, CD8, and Tbet) which was prepared at 1:300 dilution
in FACs buffer. Corresponding isotype controls were also prepared at 1:300 dilution in
FACs buffer. The washed T-cells were suspended in either DC surface marker’s antibody
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cocktail or in isotype-antibody cocktail and incubated for 60 min on ice (40C) in the dark.
The labelled cells were again washed with FACs buffer. T-cells labelled with surface
antibodies were fixed in 4% paraformaldehyde for 15 min at RT and washed by
centrifugation with excess FACs buffer. For intracellular labeling of cytokines, antibodies
and their corresponding isotype controls were prepared in pre-chilled Phosflow Buffer™
(BD Biosciences) at 1:300 dilution and keep it on ice. Fixed T-cells were centrifuged, and
4% paraformaldehyde was discarded by gentle flicking and washed one time with FACs
buffer. Fixed T-cells were permeabilized by adding 100 ul of PhosFlow Buffer™ in the dark
and on ice for 30 min. T-cells were centrifuged and the permeabilization buffer was
decanted. For intracellular cytokine staining, 100 ul of IL2, IL12, TNFα and IFNγ
(eBioscience) antibody cocktail or isotype control antibody cocktail added to T-cells and
incubated for 60 min on ice (40C) in the dark. The labelled cells were again washed with
FACs buffer and analyzed using a BD LSR-II Green Flow Cytometer (BD Biosciences).
FlowJo® and BD FACSDIVA software were used to analyze the data.

17. Immunohistochemistry and Immunofluorescence staining of tumor
tissue sections
The miniMUC4-expressing and vector control murine subcutaneous tumor
sections were evaluated for PD-L1 expression by immunohistochemistry (IHC) and for
CD4 and CD8 T-cell’s infiltration by immunofluorescence (IF). Harvested tumors were
fixed in 10% neutral buffered formalin, embedded in paraffin, and 4 μm thick sections were
placed on slides. After deparaffinizing with xylene and rehydrating with decreasing alcohol
gradients with final rehydration in MilliQ water, for IHC staining, tumor sections were
treated with 5% H2O2 in 100% methanol for 1 hour at room temperature in the dark for
quenching of endogenous peroxidases. For IF, tumor sections were treated with 100%
methanol for 1 hour at room temperature in the dark for fixing the tissue. Antigen retrieval
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was done using Tris-EDTA buffer, pH 9.0 in the microwave (1100W) at high power for 15
min. For simple hematoxylin and eosin staining of tumor tissue sections, tissue slides were
counterstained with hematoxylin and eosin, followed by dehydration with increasing
alcohol gradients, xylene washes, and mounting with a cover slip. All hematoxylin and
eosin-stained slides were shown to the pathologist for analysis and quantification.
Tissues were blocked with 2.5% normal horse serum for 3 hours, and then
incubated with a primary anti-mouse PD-L1 antibody (cc-50298, Santa Cruz
Biotechnology Inc.) at 1:200 dilution in Tris-buffered saline (TBS) at 4°C overnight. For Tcell’s IF staining, two separate tissue sections were incubated with anti-mouse CD4 or
CD8 antibodies (Thermo Fisher Scientific) respectively at 1:400 in PBS at 4°C overnight.
PD-L1 stained slides were rinsed with TBST and T-cells stained slides were washed with
PBST. After wash, PD-L1 labeled slides were incubated with an HRP-conjugated goat
anti-rabbit secondary antibody for 1 hour. T-cell’s labeled sections were incubated with
Alexa Fluor 488 conjugated goat-anti-mouse secondary antibody for 1 hour in the dark.
IHC slides were rinsed with 2 washes of TBST and 3 washes of TBS, and subsequently,
using DAB substrate kit (Vector Laboratories) the color was developed. Sections were
counterstained with hematoxylin, followed by dehydration with increasing alcohol
gradients, then xylene washes and mounting with a cover slip. IF slides were again
washed with 4 washes with PBST and two washes with PBS, followed by covering the
section with a glass slide and the anti-fade VECTASHIELD mounting media (Vector
Laboratories Inc., Burlingame, CA, USA). IF staining was observed under the Zeiss 510
LASER
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confocal

(https://imagej.nih.gov/).

microscope

and

quantified

by

ImageJ

software
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18. Statistical Analysis
For our autoantibodies analysis, the differences among group means were tested
by one-way analysis of variance (ANOVA) F-test using JMP® Data Analysis Software (SAS
Institute Inc., NC). If the F-test was significant, paired Wilcoxon sign rank t-tests were
performed for pairwise comparisons of group means. Significance was defined as p <
0.001.
For our nanovaccine in vitro, ex vivo and in vivo studies differences among group
means were tested by one-way analysis of variance (ANOVA) F-test using GraphPad
Prism v. 7.0 (GraphPad, La Jolla, CA). If the F-test was significant, Tukey’s t-tests and
Student’s t-tests were performed for pairwise comparisons of group means. Significance
was defined as p < 0.05.
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19. Table I: List of antibodies

S.No.

Antibodies

Company

Catalogue No.

1

Alexa Fluor® 700 anti-mouse CD11c
(clone N418)

eBioscience (San
Diego, CA)

56-0114-80

2

FITC conjugated anti-mouse/rat MHC
Class II (I-Ek, clone 14-4-4S)

eBioscience (San
Diego, CA)

11-5980-81

3

(APC) anti-mouse CD40 (clone 1C10)

eBioscience (San
Diego, CA)

17-0401-81

4

(PE)-Cy7 conjugated anti-mouse F4/80
(clone BM8)

eBioscience (San
Diego, CA)

25-4801-82

5

Anti-Mouse MHC Class I (H-2Kd)
eFluor® 450 (Clone: SF1-1.1.1)

eBioscience (San
Diego, CA)

48-5957-80

6

Alexa Fluor® 700 conjugated Armenian
hamster IgG (clone eBio299Arm)

eBioscience (San
Diego, CA)

56-4888-80

7

FITC IgG2a κ (clone eBR2a)

eBioscience (San
Diego, CA)

11-4321-80

8

Rat IgG2a K Isotype Control APC
(clone eBR2a)

eBioscience (San
Diego, CA)

9

PE-conjugated rat IgG2a (clone eBR2a)

eBioscience (San
Diego, CA)

12-4321-80

10

Rat IgG2a K Isotype Control PECyanine7 (clone eBR2a)

eBioscience (San
Diego, CA)

25-4321-81

11

PE/Cy7 anti-mouse CD86 (Clone GL1)

BD Biosciences

12

PE conjugated anti-mouse CD80 (clone
16-10A1)

eBioscience (San
Diego, CA)

17-4321-41
17-4321-81

560582

12-0801-81
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13

PE/Cy 5.5 antimouse CD205 (MMR,
clone NLDC-145)

BioLegend

138207

14

PerCP/Cy5.5 Rat IgG2a, κ Isotype Ctrl
Antibody

BioLegend

400531

15

Rat IgG2a K Isotype Control eFluor®
450 (clone eBR2a)

eBioscience (San
Diego, CA)

48-4321-80

16

T-bet (Anti-Human/Mouse T-bet PerCPCyanine5.5

eBioscience (San
Diego, CA)

45-5825-80

17

GATA-3 (Anti-Human/Mouse Gata-3
eFluor® 660)

eBioscience (San
Diego, CA)

50-9966-41

18

CD4 (Anti-Mouse CD4 eFluor® 450)

eBioscience (San
Diego, CA)

48-0042-80

19

CD8 (Anti-Mouse CD8a PE)

eBioscience (San
Diego, CA)

12-0081-81

20

IL-2 (Anti-Mouse IL-2 PE-Cyanine7)

eBioscience (San
Diego, CA)

25-7021-80

21

IL-10 (Anti-Mouse IL-10 FITC)

eBioscience (San
Diego, CA)

11-7101-41

22

IL-12 (Anti-Mouse IL-12/IL-23 p40 Alexa
Fluor® 488)

eBioscience (San
Diego, CA)

53-7123-80

23

IL-13 (Anti-Mouse IL-13 PE-Cyanine7)

eBioscience (San
Diego, CA)

25-7133-80

24

IFNγ (Anti-Mouse IFN gamma APC)

eBioscience (San
Diego, CA)

17-7311-81

25

Rat IgG2b Isotype Control eFluor® 660

eBioscience (San
Diego, CA)

50-4031-80

26

Rat IgG2a K Isotype Control Alexa
Fluor® 488

eBioscience (San
Diego, CA)

53-4321-80
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27

Rat IgG2b K Isotype Control FITC

eBioscience (San
Diego, CA)

11-4031-81

28

Rat IgG1 K Isotype Control eFluor® 450

eBioscience (San
Diego, CA)

48-4301-80

29

CD4 Monoclonal Antibody (RIV6)

ThermoFisher
Scientific

MA1-7631

30

CD8 Monoclonal Antibody (RIV11)

ThermoFisher
Scientific

MA1-7632

31

Pdcd-1L1 (H-130) {Discontinued
Antibody}

SantaCruz
Biotechnology INC.

Sc-50298

32

Goat Anti-mouse IgG2b-HRP

ThermoFisher
Scientific

M32407

33

Goat Anti-mouse IgG1-HRP

ThermoFisher
Scientific

A10551

34

Peroxidase AffiniPure Goat AntiHuman IgM, Fc5μfragment specific

Jackson
ImmunoResearch
Laboratories, INC.

109-035-129

35

Peroxidase AffiniPure Goat AntiHuman IgG (H+L)

Jackson
ImmunoResearch
Laboratories, INC.

109-035-003

36

Peroxidase AffiniPure Goat AntiHuman IgA + IgG + IgM (H+L)

Jackson
ImmunoResearch
Laboratories, INC.

109-035-064

37

Peroxidase AffiniPure Goat AntiHuman Serum IgA, α Chain Specific

Jackson
ImmunoResearch
Laboratories, INC.

109-035-011

38

Goat anti-Mouse IgG (H+L) CrossAdsorbed Secondary Antibody, Alexa
Fluor 488

ThermoFisher
Scientific

A-11001

39

Goat anti-Mouse IgG (H+L) Secondary
Antibody, HRP

ThermoFisher
Scientific

31430

40

Goat anti-Rabbit IgG (H+L) Secondary
Antibody, HRP

ThermoFisher
Scientific

31460
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Supplemental Table 1. Patient characteristics, all subjects

Supplemental Table 2. Patient characteristics, limited subjects
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CHAPTER 3: MUC4 AS A VACCINE
CANDIDATE FOR PC
IMMUNOTHERAPY
The material covered in this chapter is the subject of a research article

2. Banerjee K., Kshirsagar P., Kaur S., Brand RE., Smith L., Batra SK., and Jain M.
Presence of MUC4 autoantibodies in the serum of pancreatic cancer patients. (Manuscript
under Preparation)
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1. Synopsis
A major challenge in pancreatic cancer (PC) immunotherapy is identifying tumorassociated-antigens (TAAs) that can be targeted. In PC, Mucin-4 (MUC4) is differentially
overexpressed and aberrantly glycosylated, thus potentially serving as a source of neoantigenic epitopes, which could be exploited for cancer immunotherapy. Literature review
has shown that an immune response developed in the form of autoantibodies to various
tumor antigens could serve as a surrogate for immunogenicity (and compromised selftolerance) in cancer patients. The presence of MUC4 autoantibodies was analyzed in
serum samples taken from patients at the time of pancreatic cancer diagnosis prior to any
treatments, from patients with chronic pancreatitis, and healthy controls. By using indirectELISA techniques we were able to detect autoantibodies against recombinant human
MUC4-beta (MUC4β) protein in 77.41% of PC patient’s sera, whereas only 33.33% of agematched healthy controls and 23.81% of chronic pancreatitis (CP) patients had positive
sera. In addition, we used a panel of 7 MUC4-alpha region peptides and 4 MUC4β
peptides to identify highly immunogenic MUC4 epitopes. Furthermore, isotyping these
autoantibodies in PC patient sera indicates that IgM antibodies to peptides A2, D4 and B1
correlate with better prognosis. Our novel study suggests that MUC4 expressed by
pancreatic tumors is immunogenic in PC patients and could be used as a target for cancer
immunotherapy. Further these studies suggest that segregation of PC patients based on
the presence of MUC4 autoantibodies against multiple MUC4 peptide, could be helpful in
identifying patients for personalized MUC4-based immunotherapy treatment of pancreatic
cancer.
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2. Background and Rationale
Pancreatic cancer (PC) is a fatal disease with a poor 5-year overall survival of
merely 8% [1]. Conventional therapies for PC such as chemotherapy, radiation therapy
and surgery have fared with limited success, thus necessitating the need to develop
alternative treatment strategies [2, 3]. Immunotherapy has emerged as a viable option but
had stunted success in the efficacious treatment of pancreatic cancer patients [4, 5]. PC
has limited genetic mutations, notably at the KRAS codon position with 12 mutations, and
bear at the maximum 4000 potential immunogenic neoantigens, whereas melanoma has
a predicted neoantigen count of 14000 that corroborates with success seen in melanoma
immunotherapy [6-8]. Thus, one of the major challenges in PC immunotherapy is the
identification of tumor-associated antigens (TAAs) that could be specifically targeted to
cancer with negligible side-effects on healthy cells/organs.
TAAs expressed by cancer cells are mostly recognized as self-antigen due to the
overriding of the immune system by immunoediting, therefore establishing a potent
cancer-mediated tolerance against its TAAs [3, 9, 10]. Abnormal expression of antigens
by cancer cells being recognized by immune surveillance that leads to the generation of
autoantibodies is reflective of the immune response generated in cancer patients [10].
Expression of the antigen at the aberrant location where it is neither expressed in normal
organ nor during other malignancy affecting that organ makes it a lucrative target for
immune cells. In addition, post-translational modifications of such antigens affect their
processing and loading on major histocompatibility complex (MHC molecules). The
modified antigen-loaded MHC interacts with T cell receptors (TCRs), hence activating
CD4+ T helper cells to mount a humoral autoantibody response, overriding immunological
tolerance against the TAA [10, 11].
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Mucin 4 (MUC4), a high molecular weight glycoprotein, is aberrantly
overexpressed by and glycosylated in PC cancer cells, whereas it is negligibly present in
normal pancreas and chronic pancreatitis (CP) patients [12-14]. Presence of
autoantibodies against the VNTR region of another aberrantly overexpressed mucin in
PC, Mucin 1 (MUC1), has been detected in platinum based drug resistant lung and ovarian
cancers [15, 16], but there were no significant increase in MUC1 autoantibodies detected
in PC patients when compared to age-matched controls [17]. Unlike MUC1, the MUC4
expression is restricted in most of the normal organs except for low levels being expressed
in urogenital tracts and trachea in lungs [18]. In addition, autoantibodies against MUC4TR region glycopeptides have been detected in colorectal cancer patients [19]. Thus, we
hypothesized that MUC4 could be potentially immunogenic because of its spatial
expression and post-translational modifications leading to tolerance against MUC4 being
compromised in PC patients.
MUC4 has a potential autocatalytic Gly-AspPro-His (GDPH) cleavage site that
generates the N-terminal MUC4α subunit (containing the TR region) and a membranetethered MUC4β subunit [20-22]. In contrast to the published studies on MUC4
autoantibodies [19], our study encompassed the entire length of MUC4 to demonstrate
that MUC4 is immunogenic in PC patients. This design provided us a unique opportunity
to assess the development of the humoral response to the entire protein backbone of
MUC4 in PC patient serum. Due to the large molecular weight of MUC4α we were unable
to express and purify the recombinant protein in a bacterial system. We successfully
purified the MUC4β recombinant protein, which was used in our autoantibody study. Our
lab is interested in utilizing MUC4 to develop an immunotherapy strategy to treat PC.
Therefore, we also predicted potential major histocompatibility complex-I (MHC-I) HLAbinding immunogenic peptides using a reverse immunology approach [23] across the
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entire protein sequence of MUC4. Most of the available studies on cancer vaccine
immunotherapies primarily focus on HLA-binding peptides to induce T-cell mediated
responses. Humoral response analysis against such peptides have not been investigated
and thus excludes an equivalently crucial arm from factoring in the overall clinical outcome
status of vaccine-immunized patients. We predicted the B-cell probability score for the
same peptides and were keen to observe if an autoantibody signature was present against
these T-cell peptides. Our study reported the presence of circulating autoantibodies
against both MUC4β protein and MUC4 peptides present in PC patient serum when
compared to CP patient’s and healthy individual’s serum. This interesting observation
suggests that MUC4 protein could potentially stimulate both T-cells and B-cells that may
affect the overall clinical outcome.

Further, we elucidated the various isotypes of

autoantibodies present produced against MUC4 in PC patients. In addition, since the
humoral response against MUC4 serves as a surrogate of compromised tolerance, we
stratified and predicted patients who could have a higher probability of response to
personalized MUC4-based immunotherapy.

3. Results
3.1 Analysis of Circulating MUC4 Autoantibody in PC patients
The primary aim of this study was to develop a novel platform for selective
detection of circulating autoantibodies against the human MUC4β recombinant protein. To
our knowledge we are the first group to purify a recombinant human MUC4β protein, which
we have been utilized to develop the assay. Circulating autoantibodies against
recombinant human MUC4β protein was observed to be upregulated in PC patients as
compared to healthy individuals and chronic pancreatitis patients. The low level of
antibody positive sera and high level of antibody positive sera was defined at its cut-off
values of <1.283 and ≥1.283 respectively (Figure 1A). Based on the cut-off values we
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were able to determine that 76.7% of PC patients had high levels of MUC4 autoantibodies,
whereas only 37% of healthy and 28.6% of CP patients showed high levels of MUC4β
autoantibodies (Figure 1A). We didn’t observe a significant advantage in survival between
PC patients with high levels of MUC4 autoantibodies and low levels of MUC4
autoantibodies (Figure 1B). Further we performed stage-wise analysis and observed that
86.7% of early-stage PC patients and 66.7% of late-stage patients had circulating MUC4
autoantibodies in their sera (Figure 1C). PC patient survival days analysis demonstrated
that patients with higher serum reactivity had mean survival days (MSD) of 179 days for
Stage 1-II and 309 days for Stage II-IV, compared to the patients with lower serum
reactivity had MSD of 131 days for Stage 1-II and 244 days for Stage II-IV (Figure 1C).

3.2 Bioinformatics Analysis Predicts Potential MUC4 Peptides
Due to the difficulty in purification of the MUC4α domain, we predicted potential
adequate HLA-binding immunogenic MHC-I peptides inside both MUC4α and MUC4β
domains to capture the entire MUC4 protein. A prerequisite for an immune response to
arm, immunogenic peptides of MUC4 must be loaded on major histocompatibility
complexes that would be cross-represented to effector immune cells (i.e. T-cells and Bcells). HLA-A2 is one of the widely used HLA-subtype for peptide predictions that have
been used in designing vaccinations for melanoma and lung cancer [29, 37-39]. We used
3 prediction tools NetCTL1.0 and IEDB (Tepi Tool and Peptide processing) for determining
HLA A2-binding T cell epitopes. NetCTL1.0 (based on a combined prediction of peptide
MHC binding, proteasomal C terminal cleavage and TAP transport efficiency) software
analyzed MUC4 sequence and predicted potential HLA-binding 9-mer amino acid
sequences scored across 10 major human HLA-A2 isoforms. Peptides with combined high
scores have higher specificity, sensitivity and higher affinity binding to HLA-A2 MHC-I
complex. We further analyzed these peptides using IEDB (http://tools.iedb.org/tepitool/)
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prediction TepiTool which is based on consensus method employing artificial neural
network, combinatorial library networks and SMM-align. TepiTool scored the NetCTL1.0
predicted peptides based on their likelihood to bind to human HLA-A2*02.1 (mostly used
in vaccine studies [39]), as well as, C57BL/6 mouse HLA-Db and HLA-Kb MHC-I isotypes.
In addition IEDB Processing (http://tools.iedb.org/processing/) analysis, which scores
based on proteasomal C terminal cleavage, TAP transport efficiency and MHC-I complex
loading, ranked these predicted peptides for both mouse and human HLA MHC-I loading.
Lower predicted rank score suggests a higher probability of these peptides to be loaded
on MHC-I complex and cross-presented to T-cells for activating them in an antigenspecific manner (Figure 2).
Our autoantibody analysis demonstrated MUC4β specific antibodies being
generated specifically in PC patients. Bioinformatics analysis predicted MHC-I peptides in
MUC4β region that made us curious to analyze the potential of these peptides to serve as
B-cell immunogenic epitopes. For the same, we ran and scored these peptides on the
IEDB B-cell prediction tool (http://tools.iedb.org/bcell/) and performed BCPred analysis
(http://ailab.ist.psu.edu/bcpred/predict.html). Our B-cell epitope analysis showed that
there was a difference in predicted scores between each peptide. Only 13 out of 24
predicted peptides were picked up by both prediction software and scored for the potential
of them getting recognized by B-cells. We ranked these peptides based on their BCPred
scores (Figure 3), and randomly selected peptides that represent all differentially scored
B-cell epitope regions of both MUC4α and MUC4β to elucidate the plausibility of
autoantibodies generated against these predicted peptides.

3.3 Screening of Autoantibody Signature against MUC4 Peptides
Our initial experiment elucidated the presence of autoantibodies against a MUC4β
recombinant protein which provides a large repertoire of epitopes that could be recognized
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by B cells. In addition, our bioinformatics analysis predicted peptides that have the
potential to serve as both T-cell and B-cell epitopes. To validate our observations, we
developed a modified indirect ELISA to detect autoantibodies if any, generated against
these epitopes. Our ELISA studies revealed differential serum reactivity to each of the 7
MUC4α peptides whereas significantly low/ reactivity was seen against TR and PD2
peptides and 5 µg/ml of BSA protein (Figure 4A). Further, we were curious to understand
whether any peptide specifically fared better when compared to the survival status of PC
patients. Our study showed that patients with high serum reactivity to peptides D3 and F3
survived longer than their low serum reactivity counterparts, but the rest of the 5 MUC4α
peptides didn’t show similar relationship (Figure 4B).
Similarly, PC patient serum significantly reacted with all 4 peptides from MUC4β
region and low reactivity was observed with control peptides and protein (Figure 5A). In
addition, high serum reactivity to MUC4β peptides didn’t provide a survival advantage
(Figure 5B). Thus, our study shows for the first time that MUC4 MHC-I HLA-binding T-cell
peptides could potentially be recognized by B-cells and might have a dual (activate both
cellular and humoral immune pathway) epitope property. Further, we stratified PC patients
with high autoantibody levels detected in their sera and observed that we could potentially
design a selection strategy to elucidate patients who likely might have compromised
peripheral tolerance (Table I). To ensure the specificity of the detected antibodies, we
compared the serum reactivity of randomly selected 10 healthy and 10 chronic pancreatitis
individuals and we observed that PC patient specific reactivity was seen to all 11 MUC4
peptides and negative in healthy or CP individuals (Supplemental Figure 1 & 2).

3.4 Isotype Analysis of MUC4 Autoantibodies in PC Patients
Autoantibody isotypes such as IgM autoantibodies in cancer patient serum have
been shown to correlate with poor prognosis and overall survival of those patients [15].
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Activation of B-cells to its mature form after receiving secondary stimulation from CD4+ Tcells induces isotype switching to generate various classes of antibodies with the same
variable antigen binding region as the original antibody generated to the antigen by the
VD (J) recombination pathway [40, 41]. Our observations demonstrated that
autoantibodies are present against both recombinant MUC4 protein and its peptides, but
higher levels of these autoantibodies didn’t significantly correlate with patient survival data.
Isotyping of mucin autoantibodies could provide some insight into understanding whether
activation of B-cells confers any survival advantage to PC patients. We measured different
isotypes (IgA, IgM and IgG) of MUC4 autoantibodies present in PC patient sera and
correlated with overall patient survival and prognosis. All three MUC4β protein
autoantibody isotypes were detected, however presence of IgG isotype autoantibodies in
serum segregated PC patients in two groups. Despite the segregation, we didn’t observe
any significant correlation between autoantibody isotypes and patient survival
(Supplemental Figure 3).
Isotype analysis of autoantibodies against MUC4α peptides demonstrated
differential levels of isotypes present in PC patient serum (Figure 6A). Our data further
elucidated that high levels of IgM autoantibody against A2 and D4 MUC4α peptides
correlate strongly with overall patient survival (P<0.001) (Figure 6B). Analysis of MUC4β
peptides also demonstrated that all isotypes were detected (Figure 7A). Similarly, KaplanMeier graph shows that high levels of IgM autoantibody to B1 peptide correlated strongly
with PC survival (Figure 7B). Our data showed that MUC4 is not only immunogenic in PC
patients but also induces maturation of B-cells. Interestingly, for all MUC4 peptides,
patients with IgM isotype autoantibodies had better median survival than patients with
either IgG or IgA autoantibodies (Supplemental Figure 4).
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4. Discussion
The present study investigated the possibility of MUC4 being immunogenic in PC
patients. We developed a modified ELISA strategy and tested both MUC4 recombinant
protein and peptides to determine the presence of autoantibodies in patient sera. MUC4
is aberrantly overexpressed in PC patients and its expression increases with gradual
progression of the malignancy [42]. MUC4 overexpression and aberrant glycosylation in
PC and its absence in the normal pancreas [14] makes it a potential antigen that might
get recognized by the immune system (specifically by B-cells). The modified indirect
ELISA discovery platform for detecting human serum autoantibodies was developed for
efficient antigen-antibody binding and provide a remarkably low background. Cancerassociated autoantibodies to recombinant MUC4β protein were identified in PC patient
sera, whereas healthy individuals and CP patients were negligible for MUC4
autoantibodies, although survival analysis didn’t reveal any robust correlation with levels
of autoantibodies present in PC patient sera. Presence of circulating MUC4 autoantibodies
in PC patients therefore supports the hypothesis that immunological tolerance is
compromised against MUC4 and gets recognized by B-cells.
In our study, we utilized both recombinant protein and peptides to investigate
whether different domains/regions of MUC4 is immunogenic other than just the TR region
sequence that is well studied. Bioinformatics analysis predicted HLA-binding peptides that
have potential to serve as a dual epitopes for both cellular and humoral immune pathways
in human as well as in mouse. To capture MUC4α region we randomly selected peptides
corresponding to that region due to unavailability of purified recombinant MUC4α protein.
The rationale behind using peptides of MUC4β region was to recognize immunodominant
region present in MUC4β protein and it was investigated on a peptide-based ELISA
platform. Our study revealed that only PC patient serum contained autoantibodies against
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MUC4 peptides, whereas there was negligible reactivity detected in control individuals.
Our patient stratification strategy based on their serum reactivity with respective MUC4
peptides elucidate that the tolerance against each peptide is compromised in patient-topatient basis. Such case basis-compromised tolerance might correlate with the differential
response of PC patients to MUC4-based immunotherapy that needs to be investigated in
the future.
Detection of specific autoantibody isotypes suggests activation and maturation of
B-cells leading to the systemic availability of neutralizing antibodies protecting against
cancer, which could be translated to the observed negative correlation of immature IgM
antibodies with the survival of patients [15, 19]. Our data in contrast showed that high
levels of IgM autoantibodies against A2, D4 and B1 have a statistically strong correlation
with longer survival of PC patients. Further, PC patients with high levels of IgM
autoantibodies have better survival than those who have IgG/IgA circulating
autoantibodies, thus making a case for a better understanding of the role of humoral
responses in the survival of patients.
Overall our studies provide enough evidence to suggest that entire MUC4 is
immunogenic and peripheral tolerance to MUC4 is compromised in PC patients. In a
recent study, it has been shown that CD8+ T cell-specific MUC16 neoantigen epitopes
provide a survival advantage to PC patients [43]. Interestingly our data for the first time
reveals that T-cell epitopes located on various regions of the MUC4 protein sequence
(excluding VNTR region), could simultaneously be recognized by B-cells and activate the
humoral arm of the immune system. Further, circulating IgM MUC4 autoantibodies against
particular peptides, showed to provide protection to the PC patients and correlates with
increased overall survival status. Cancer vaccines have emerged as an alternative
treatment modality for cancer patients who respond poorly to traditional therapies. An
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efficient vaccine-mediated immunity requires strong activation of both humoral (antibody
and memory B-cell generation) and cellular responses (activation of both CD4+ helper Tcells, CD8+ cytotoxic T cells and memory T-cells), which provides optimal protection from
the disease [44]. We propose that the dual antigenic (activate both B & T cells) epitope
quality and aberrant expression of MUC4 in all the stages of PC tumor development
qualifies it to be a strong candidate for immunotherapy strategies like cancer vaccines.
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Table I: Autoantibodies reactivity against MUC4 peptides can predict
patients with compromised tolerance
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Figure 1: Autoantibodies against MUC4β were detected in PC patient serum.
Indirect ELISA study revealed that PC patients had high expression of
circulating autoantibodies to recombinant human MUC4β protein (A). The high
levels of MUC4 autoantibodies didn’t correlate with PC survival as seen in KaplanMeier graph (B). Further analysis showed that patients with high levels of MUC4
autoantibodies, both at early (Stage I-II) and late (Stage IV) stages of PC, had
longer survival than patients with low levels of autoantibodies (C).
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Figure 1
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Figure 2: Bioinformatics analysis predicted T-cell immunodominant epitopes
of MUC4.
NetCTL1.0 and IEDB software analysis based on combined prediction of
peptide MHC binding, proteasomal C terminal cleavage and TAP transport
efficiency, predicted and ranked T-cell immunodominant epitopes. Lower predicted
rank score suggests a higher probability of these peptides to be loaded on MHC-I
complex and cross-represented to T-cells for activating them in an antigen-specific
manner.
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Figure 3: Bioinformatics analysis predicted B-cell immunodominant
epitopes of MUC4.
IEDB B-cell prediction software analysis based on sequence characteristics
of the antigen using amino acid scales and HMMs, predicted and ranked B-cell
immunodominant epitopes. High predicted rank score suggests higher probability
of these peptides to be recognized by B-cells.
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115

Figure 4: Reactivity against predicted MUC4α epitopes was found in PC
patients.
Indirect ELISA study demonstrated that PC patient serum contains
circulating autoantibodies against MUC4α immunodominant predicted epitopes,
whereas low reactivity to PD2 internal protein control was observed. The serum
reactivity to MUC4 α was observed to be significantly higher than PD2 and TR
control peptides (A). Presence of autoantibodies against these peptides didn’t
confer any survival advantage (B). ANOVA analysis of group means was
significant (P<0.001), ** and ** denotes paired T-test between PD2 vs. MUC4
peptides and TR vs peptides respectively (P<0.001)
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Figure 5: Reactivity against predicted MUC4β epitopes was found in PC
patients.
Indirect ELISA study demonstrated that PC patient serum contains
circulating autoantibodies against MUC4β immunodominant predicted epitopes,
whereas low reactivity to PD2 internal protein control was observed. The serum
reactivity to MUC4 α was observed to be significantly higher than PD2 and TR
control peptides (A). Presence of autoantibodies against these peptides didn’t
confer any survival advantage (B). ANOVA analysis of group means was
significant (P<0.001), ** and ** denotes paired T-test between PD2 vs. MUC4
peptides and TR vs peptides respectively (P<0.001)
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Figure 6: IgM autoantibodies to MUC4α peptides show a better prognosis in
PC patients.
Isotyping analysis revealed that differential levels of all three IgM, IgG and
IgA isotypes have been detected against all MUC4α peptides (A). Kaplan-Meier
graph shows that high levels of IgM autoantibodies to A2 and D4 (blue arrows)
significantly correlated with PC patient survival (MSD: 344 days & 535 days
respectively).
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Figure 7: IgM autoantibodies to MUC4β peptides show a better prognosis in
PC patients.
Isotype analysis revealed that differential levels of all three IgM, IgG and
IgA isotypes have been detected against all MUC4β peptides (A). Kaplan-Meier
graph shows that high levels of IgM autoantibodies to B1 (blue arrow) significantly
correlated with PC patient survival (MSD: 344 days).
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Figure 7
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Supplemental Figure 1: Reactivity against predicted MUC4α epitopes was
found only in PC patients.
PC specific reactivity was found against MUC4α peptides with significantly
low reactivity in both healthy and CP controls, suggesting that these peptides could
serve as unique immunodominant epitopes being immunologically recognized
specifically by PC patient’s immune system.
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Supplemental Figure 1
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Supplemental Figure 2: Reactivity against predicted MUC4β epitopes was
found only in PC patients.
PC specific reactivity was found against MUC4β peptides with significantly
low reactivity in both healthy and CP controls, suggesting that these peptides could
serve as unique immunodominant epitopes being immunologically recognized
specifically by PC patient’s immune system.
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Supplemental Figure 2
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Supplemental Figure 3: Isotyping of MUC4 circulating antibodies didn’t show
any correlation with survival status of PC patients.
Isotype analysis of autoantibodies to recombinant human MUC4β protein
showed that PC patients could be segregated on the levels of IgG autoantibodies
present in PC patient serum. However, none of these isotypes correlated with PC
patient survival.
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Supplemental Figure 3
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Supplemental Figure 4: Autoantibodies isotype to MUC4α and MUC4β
peptides reveals a differential correlation with patient survival.
Correlation of PC patient survival with isotypes of autoantibodies to MUC4
peptides present in patient sera demonstrates that high levels of IgM
autoantibodies seem to positively correlate with patient survival compared to IgG
or IgA autoantibodies for all peptides.
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131

References
[1] R.L. Siegel, K.D. Miller, A. Jemal, Cancer statistics, 2018, CA Cancer J Clin, 68 (2018)
7-30.
[2] K. Banerjee, S. Kumar, K.A. Ross, S. Gautam, B. Poelaert, M.W. Nasser, A. Aithal, R.
Bhatia, M.J. Wannemuehler, B. Narasimhan, J.C. Solheim, S.K. Batra, M. Jain, Emerging
trends in the immunotherapy of pancreatic cancer, Cancer Lett, 417 (2018) 35-46.
[3] K. Sideras, H. Braat, J. Kwekkeboom, C.H. van Eijck, M.P. Peppelenbosch, S. Sleijfer,
M. Bruno, Role of the immune system in pancreatic cancer progression and immune
modulating treatment strategies, Cancer Treat Rev, 40 (2014) 513-522.
[4] L.R. Brunet, T. Hagemann, G. Andrew, S. Mudan, A. Marabelle, Have lessons from
past failures brought us closer to the success of immunotherapy in metastatic pancreatic
cancer?, Oncoimmunology, 5 (2016) e1112942.
[5] L.M. Matrisian, J.D. Berlin, The Past, Present, and Future of Pancreatic Cancer Clinical
Trials, Am Soc Clin Oncol Educ Book, 35 (2016) e205-215.
[6] P. Bailey, D.K. Chang, M.A. Forget, F.A. Lucas, H.A. Alvarez, C. Haymaker, C.
Chattopadhyay, S.H. Kim, S. Ekmekcioglu, E.A. Grimm, A.V. Biankin, P. Hwu, A. Maitra,
J. Roszik, Exploiting the neoantigen landscape for immunotherapy of pancreatic ductal
adenocarcinoma, Sci Rep, 6 (2016) 35848.
[7] L.B. Alexandrov, S. Nik-Zainal, D.C. Wedge, P.J. Campbell, M.R. Stratton, Deciphering
signatures of mutational processes operative in human cancer, Cell Rep, 3 (2013) 246259.
[8] M.S. Lawrence, P. Stojanov, P. Polak, G.V. Kryukov, K. Cibulskis, A. Sivachenko, S.L.
Carter, C. Stewart, C.H. Mermel, S.A. Roberts, A. Kiezun, P.S. Hammerman, A. McKenna,
Y. Drier, L. Zou, A.H. Ramos, T.J. Pugh, N. Stransky, E. Helman, J. Kim, C. Sougnez, L.
Ambrogio, E. Nickerson, E. Shefler, M.L. Cortes, D. Auclair, G. Saksena, D. Voet, M.

132
Noble, D. DiCara, P. Lin, L. Lichtenstein, D.I. Heiman, T. Fennell, M. Imielinski, B.
Hernandez, E. Hodis, S. Baca, A.M. Dulak, J. Lohr, D.A. Landau, C.J. Wu, J. MelendezZajgla, A. Hidalgo-Miranda, A. Koren, S.A. McCarroll, J. Mora, B. Crompton, R. Onofrio,
M. Parkin, W. Winckler, K. Ardlie, S.B. Gabriel, C.W.M. Roberts, J.A. Biegel, K. Stegmaier,
A.J. Bass, L.A. Garraway, M. Meyerson, T.R. Golub, D.A. Gordenin, S. Sunyaev, E.S.
Lander, G. Getz, Mutational heterogeneity in cancer and the search for new cancerassociated genes, Nature, 499 (2013) 214-218.
[9] D. Delitto, S.M. Wallet, S.J. Hughes, Targeting tumor tolerance: A new hope for
pancreatic cancer therapy?, Pharmacol Ther, 166 (2016) 9-29.
[10] P. Zaenker, E.S. Gray, M.R. Ziman, Autoantibody Production in Cancer--The Humoral
Immune Response toward Autologous Antigens in Cancer Patients, Autoimmun Rev, 15
(2016) 477-483.
[11] H.H. Wandall, O. Blixt, M.A. Tarp, J.W. Pedersen, E.P. Bennett, U. Mandel, G.
Ragupathi, P.O. Livingston, M.A. Hollingsworth, J. Taylor-Papadimitriou, J. Burchell, H.
Clausen, Cancer biomarkers defined by autoantibody signatures to aberrant Oglycopeptide epitopes, Cancer Res, 70 (2010) 1306-1313.
[12] M. Andrianifahanana, N. Moniaux, B.M. Schmied, J. Ringel, H. Friess, M.A.
Hollingsworth, M.W. Buchler, J.P. Aubert, S.K. Batra, Mucin (MUC) gene expression in
human pancreatic adenocarcinoma and chronic pancreatitis: a potential role of MUC4 as
a tumor marker of diagnostic significance, Clin Cancer Res, 7 (2001) 4033-4040.
[13] S. Carrara, M.G. Cangi, P.G. Arcidiacono, F. Perri, M.C. Petrone, G. Mezzi, C.
Boemo, A. Talarico, E.D. Cin, G. Grassini, C. Doglioni, P.A. Testoni, Mucin expression
pattern in pancreatic diseases: findings from EUS-guided fine-needle aspiration biopsies,
Am J Gastroenterol, 106 (2011) 1359-1363.

133
[14] S.K. Gautam, S. Kumar, A. Cannon, B. Hall, R. Bhatia, M.W. Nasser, S. Mahapatra,
S.K. Batra, M. Jain, MUC4 mucin- a therapeutic target for pancreatic ductal
adenocarcinoma, Expert Opin Ther Targets, 21 (2017) 657-669.
[15] R.A. Budiu, G. Mantia-Smaldone, E. Elishaev, T. Chu, J. Thaller, K. McCabe, D.
Lenzner, R.P. Edwards, A.M. Vlad, Soluble MUC1 and serum MUC1-specific antibodies
are potential prognostic biomarkers for platinum-resistant ovarian cancer, Cancer
Immunol Immunother, 60 (2011) 975-984.
[16] Y. Hirasawa, N. Kohno, A. Yokoyama, K. Kondo, K. Hiwada, M. Miyake, Natural
autoantibody to MUC1 is a prognostic indicator for non-small cell lung cancer, Am J Respir
Crit Care Med, 161 (2000) 589-594.
[17] B. Burford, A. Gentry-Maharaj, R. Graham, D. Allen, J.W. Pedersen, A.S. Nudelman,
O. Blixt, E.O. Fourkala, D. Bueti, A. Dawnay, J. Ford, R. Desai, L. David, P. Trinder, B.
Acres, T. Schwientek, A. Gammerman, C.A. Reis, L. Silva, H. Osorio, R. Hallett, H.H.
Wandall, U. Mandel, M.A. Hollingsworth, I. Jacobs, I. Fentiman, H. Clausen, J. TaylorPapadimitriou, U. Menon, J.M. Burchell, Autoantibodies to MUC1 glycopeptides cannot
be used as a screening assay for early detection of breast, ovarian, lung or pancreatic
cancer, Br J Cancer, 108 (2013) 2045-2055.
[18] P. Chaturvedi, A.P. Singh, S.K. Batra, Structure, evolution, and biology of the MUC4
mucin, FASEB J, 22 (2008) 966-981.
[19] J.W. Pedersen, A. Gentry-Maharaj, A. Nostdal, E.O. Fourkala, A. Dawnay, M. Burnell,
A. Zaikin, J. Burchell, J.T. Papadimitriou, H. Clausen, I. Jacobs, U. Menon, H.H. Wandall,
Cancer-associated autoantibodies to MUC1 and MUC4--a blinded case-control study of
colorectal cancer in UK collaborative trial of ovarian cancer screening, Int J Cancer, 134
(2014) 2180-2188.

134
[20] N. Moniaux, F. Escande, S.K. Batra, N. Porchet, A. Laine, J.P. Aubert, Alternative
splicing generates a family of putative secreted and membrane-associated MUC4 mucins,
Eur J Biochem, 267 (2000) 4536-4544.
[21] N. Moniaux, F. Escande, N. Porchet, J.P. Aubert, S.K. Batra, Structural organization
and classification of the human mucin genes, Front Biosci, 6 (2001) D1192-1206.
[22] N. Moniaux, S. Nollet, N. Porchet, P. Degand, A. Laine, J.P. Aubert, Complete
sequence of the human mucin MUC4: a putative cell membrane-associated mucin,
Biochem J, 338 ( Pt 2) (1999) 325-333.
[23] N. Vigneron, Human Tumor Antigens and Cancer Immunotherapy, Biomed Res Int,
2015 (2015) 948501.
[24] M. Andreatta, M. Nielsen, Gapped sequence alignment using artificial neural
networks: application to the MHC class I system, Bioinformatics, 32 (2016) 511-517.
[25] Y. Kim, J. Ponomarenko, Z. Zhu, D. Tamang, P. Wang, J. Greenbaum, C.
Lundegaard, A. Sette, O. Lund, P.E. Bourne, M. Nielsen, B. Peters, Immune epitope
database analysis resource, Nucleic Acids Res, 40 (2012) W525-530.
[26] C. Lundegaard, K. Lamberth, M. Harndahl, S. Buus, O. Lund, M. Nielsen, NetMHC3.0: accurate web accessible predictions of human, mouse and monkey MHC class I
affinities for peptides of length 8-11, Nucleic Acids Res, 36 (2008) W509-512.
[27] J. Sidney, E. Assarsson, C. Moore, S. Ngo, C. Pinilla, A. Sette, B. Peters, Quantitative
peptide binding motifs for 19 human and mouse MHC class I molecules derived using
positional scanning combinatorial peptide libraries, Immunome Res, 4 (2008) 2.
[28] P. Wang, J. Sidney, C. Dow, B. Mothe, A. Sette, B. Peters, A systematic assessment
of MHC class II peptide binding predictions and evaluation of a consensus approach,
PLoS Comput Biol, 4 (2008) e1000048.
[29] P. Wang, J. Sidney, Y. Kim, A. Sette, O. Lund, M. Nielsen, B. Peters, Peptide binding
predictions for HLA DR, DP and DQ molecules, BMC Bioinformatics, 11 (2010) 568.

135
[30] M. Nielsen, C. Lundegaard, P. Worning, S.L. Lauemoller, K. Lamberth, S. Buus, S.
Brunak, O. Lund, Reliable prediction of T-cell epitopes using neural networks with novel
sequence representations, Protein Sci, 12 (2003) 1007-1017.
[31] B. Peters, A. Sette, Generating quantitative models describing the sequence
specificity of biological processes with the stabilized matrix method, BMC Bioinformatics,
6 (2005) 132.
[32] S. Paul, J. Sidney, A. Sette, B. Peters, TepiTool: A Pipeline for Computational
Prediction of T Cell Epitope Candidates, Curr Protoc Immunol, 114 (2016) 18 19 11-18 19
24.
[33] M.V. Larsen, C. Lundegaard, K. Lamberth, S. Buus, S. Brunak, O. Lund, M. Nielsen,
An integrative approach to CTL epitope prediction: a combined algorithm integrating MHC
class I binding, TAP transport efficiency, and proteasomal cleavage predictions, Eur J
Immunol, 35 (2005) 2295-2303.
[34] J.E. Larsen, O. Lund, M. Nielsen, Improved method for predicting linear B-cell
epitopes, Immunome Res, 2 (2006) 2.
[35] A. Choudhury, N. Moniaux, J.P. Winpenny, M.A. Hollingsworth, J.P. Aubert, S.K.
Batra, Human MUC4 mucin cDNA and its variants in pancreatic carcinoma, J Biochem,
128 (2000) 233-243.
[36] F. Escande, L. Lemaitre, N. Moniaux, S.K. Batra, J.P. Aubert, M.P. Buisine, Genomic
organization of MUC4 mucin gene. Towards the characterization of splice variants, Eur J
Biochem, 269 (2002) 3637-3644.
[37] M.A. Player, K.C. Barracchini, T.B. Simonis, L. Rivoltini, F. Arienti, C. Castelli, A.
Mazzocchi, F. Belli, G. Parmiani, F.M. Marincola, Differences in frequency distribution of
HLA-A2 subtypes between North American and Italian white melanoma patients:
relevance for epitope specific vaccination protocols, J Immunother Emphasis Tumor
Immunol, 19 (1996) 357-363.

136
[38] L. Rivoltini, D.J. Loftus, K. Barracchini, F. Arienti, A. Mazzocchi, W.E. Biddison, M.L.
Salgaller, E. Appella, G. Parmiani, F.M. Marincola, Binding and presentation of peptides
derived from melanoma antigens MART-1 and glycoprotein-100 by HLA-A2 subtypes.
Implications for peptide-based immunotherapy, J Immunol, 156 (1996) 3882-3891.
[39] P.O. Flores-Villanueva, M. Ganachari, H. Guio, J.A. Mejia, J. Granados, An Isolated
TCR alphabeta Restricted by HLA-A*02:01/CT37 Peptide Redirecting CD8(+) T Cells To
Kill and Secrete IFN-gamma in Response to Lung Adenocarcinoma Cell Lines, J Immunol,
(2018).
[40] E. Market, F.N. Papavasiliou, V(D)J recombination and the evolution of the adaptive
immune system, PLoS Biol, 1 (2003) E16.
[41] J. Stavnezer, C.T. Amemiya, Evolution of isotype switching, Semin Immunol, 16
(2004) 257-275.
[42] M.J. Swartz, S.K. Batra, G.C. Varshney, M.A. Hollingsworth, C.J. Yeo, J.L. Cameron,
R.E. Wilentz, R.H. Hruban, P. Argani, MUC4 expression increases progressively in
pancreatic intraepithelial neoplasia, Am J Clin Pathol, 117 (2002) 791-796.
[43] V.P. Balachandran, M. Luksza, J.N. Zhao, V. Makarov, J.A. Moral, R. Remark, B.
Herbst, G. Askan, U. Bhanot, Y. Senbabaoglu, D.K. Wells, C.I.O. Cary, O. Grbovic-Huezo,
M. Attiyeh, B. Medina, J. Zhang, J. Loo, J. Saglimbeni, M. Abu-Akeel, R. Zappasodi, N.
Riaz, M. Smoragiewicz, Z.L. Kelley, O. Basturk, I. Australian Pancreatic Cancer Genome,
R. Garvan Institute of Medical, H. Prince of Wales, H. Royal North Shore, G. University of,
H. St Vincent's, Q.B.M.R. Institute, C.f.C.R. University of Melbourne, I.f.M.B. University of
Queensland, H. Bankstown, H. Liverpool, C.O.B.L. Royal Prince Alfred Hospital, H.
Westmead, H. Fremantle, H. St John of God, H. Royal Adelaide, C. Flinders Medical, P.
Envoi, H. Princess Alexandria, H. Austin, I. Johns Hopkins Medical, A.R.-N.C.f.A.R.o.
Cancer, M. Gonen, A.J. Levine, P.J. Allen, D.T. Fearon, M. Merad, S. Gnjatic, C.A.
Iacobuzio-Donahue, J.D. Wolchok, R.P. DeMatteo, T.A. Chan, B.D. Greenbaum, T.

137
Merghoub, S.D. Leach, Identification of unique neoantigen qualities in long-term survivors
of pancreatic cancer, Nature, 551 (2017) 512-516.
[44] I.J. Amanna, M.K. Slifka, Contributions of humoral and cellular immunity to vaccineinduced protection in humans, Virology, 411 (2011) 206-215.

138

CHAPTER 4: DEVELOPMENT OF
MUC4 NANOVACCINE
The material covered in this chapter is the subject of a research article

2. Banerjee K.1#, Gautam S.1#, Kshirsagar P., Ross KA., Spagnol G., Sorgen P.,
Wannemuehler MJ., Narasimhan B., Solheim J., Kumar S., Batra SK., and Jain M.
Recombinant MUC4 nanovaccine activates dendritic cells and induces potent anti-tumor
immunity. (Submitted)
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1. Synopsis
Mucin 4 (MUC4) is high molecular weight glycoprotein that is differentially
overexpressed in pancreatic cancer (PC) and functionally contributes to disease
progression while its expression correlates with poor survival. Further, due to its aberrant
glycosylation and extensive splicing in cancer, MUC4 is a potential target for cancer
immunotherapy. Our previous studies have demonstrated the utility of amphiphilic
polyanhydride nanoparticles as a useful platform for the development of protein-based
prophylactic and therapeutic vaccines. In present study, we encapsulated purified
recombinant human MUC4 (MUC4β) protein in 20:80 ratio of amphiphilic polyanhydride
(CPTEG & CPH) adjuvants (MUC4-nanovaccine) and evaluated its ability to activate
dendritic cells and induce anti-tumor immunity. Immature dendritic cells when pulsed with
MUC4-nanovaccine exhibited more than 2-fold increase in surface expression of
activation markers (MHC-II and MHC-I) and 1.5-fold increase in pro-inflammatory
cytokines (IFN-γ, IL-6, and IL-2) levels as compared to cells exposed to MUC4β alone or
MUC4β mixed with blank nanoparticles (MUC4 +NP). Further, the antibody analysis in the
sera collected from immunized mice showed two-fold higher levels of IgG2b antibodies
than IgG1 antibodies, suggesting a predominantly Th1-type of immune response in
MUC4-nanovaccine group. Thus, our findings demonstrate MUC4-nanoformulation as a
novel platform for PC vaccine development.
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2. Background and Rationale
Pancreatic cancer (PC) has a dismal prognosis with an overall survival rate of 8%,
due to the limited efficacy of existing treatment modalities like surgery, chemotherapy, and
radiation [1, 2]. Furthermore, PC has an elaborate immunosuppressive tumor
microenvironment comprising of high desmoplasia, immune-suppressive cells and an antiinflammatory cytokine milieu [3]. Due to high level of chemotherapy-induced toxicity, PC
patients seldom benefit from chemotherapy. Recent studies have shown that
immunotherapy-based strategies like cancer vaccines can provide therapeutic benefit by
breaking the tolerance, overcoming immunosuppression and thereby, improving the
overall survival and quality of life [4, 5]. However, the development of anti-cancer vaccines
are rather more arduous due to the challenges in finding optimal tumor-associated
antigens (TAAs), because the majority of these antigens behave as “self”, and therefore,
are immunologically ignored by the host immune system leading to development of
tolerance against TAAs [4].
Mucins are high molecular-weight glycoproteins that are overexpressed on
pancreatic tumor cells and have oncogenic functions in PC pathogenesis. MUC family
members have emerged as TAAs for PC and are currently being exploited for cancer
immunotherapy. Mucin1 (MUC1) is one of the well-studied targets for PC vaccine studies
[6]. MUC1 peptide and glycopeptide vaccine studies have shown the potential of
reprogramming the immune system against mucins and generating anti-tumor responses
in various malignancies [7-12]. However, limited immunogenic epitopes provided by
peptide-based MUC1 vaccines have achieved suboptimal clinical success in PC patients
[9, 13, 14]. Unlike MUC1, Mucin4 (MUC4) is undetectable in normal pancreatic tissue and
its expression progressively increases with disease progression and [15]. MUC4 is
putatively cleaved at a Gly-AspPro-His (GDPH) site in an autocatalytic manner into two

141
subunits: a large N-terminal MUC4α containing the tandem repeat region and a smaller
membrane-tethered MUC4β [16-18]. The membrane-tethered MUC4β region is considered
functionally important as it has 3 EGF-like domains that interact with HER-2 and promote
cell proliferation. Further, targeting MUC4β is simplified since the subunit will still be
present on the cell surface of PC tumor cells post-cleavage due to its transmembrane
region. In a study, mice immunized with MUC4 glycopeptides mixed with tetanus toxin
induced strong immune responses and predominantly produced IgG1 antibodies [19].
Such “cherry-picked” immunodominant peptides limit the epitopes that can be employed
to elicit immune response in an unbiased manner, are of limited translation values. While
large size of MUC4 can potentially provide a large epitope repertoire for eliciting potent
immune response, it also makes the production and purification of intact protein equally
challenging. We thus investigated the utility of recombinant MUC4β-domain for cancer
vaccine development. To circumvent these, we investigated the utility of recombinant
MUC4β subunit for tumor vaccine development.
One of the major challenges of vaccine delivery vehicles is to ensure protein
stability and release over a sustained period in circulation [20, 21]. Amphiphilic
polyanhydride nanoparticles, composed of 1,8-bis(p-carboxyphenoxy)-3,6-dioxaoctane
(CPTEG) and 1,6-bis(p-carboxyphenoxy)hexane (CPH), have been shown to stabilize the
structure and activity of encapsulated proteins while providing sustained release via a
surface erosion mechanism [22, 23]. Furthermore, these nanoparticles have been shown
to be readily internalized by antigen presenting cells (APCs), such as dendritic cells and
macrophages, leading to the upregulation of surface activation markers including major
histocompatibility complexes class I and II (MHC-I & MHC-II), co-activating ligands (CD86,
CD40), secretion of inflammatory cytokines and generation of humoral responses [24-27].
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In the present study, we encapsulated endotoxin free recombinant human MUC4β
in 20:80 CPTEG:CPH nanoparticles (MUC4-nanovaccine). We investigated the
relationships between antigen release kinetics, immunological activity in terms of APC
activation, and induction of humoral responses by the MUC4-nanovaccine. Our study
demonstrates that the MUC4-nanovaccione activated mature DCs, eliciting a Th1 type of
immune response. We further observe that MUC4 nanovaccine-immunized mice generate
more IgG2b anti-MUC4β serum antibodies than IgG1 antibodies, suggesting that MUC4nanovaccine elicits a predominantly Th1-type response. Therefore, recombinant human
MUC4β-based polyanhydride nanovaccine has the potential to be an effective
immunotherapy against pancreatic cancer and other MUC4 overexpressing malignancies.

3. Results
3.1 Encapsulation of MUC4β into Polyanhydride Nanoparticles Provides
Sustained Antigen Release Kinetics
The 20:80 CPTEG:CPH nanoparticles loaded with 3 wt. % MUC4β were synthesized via
solid-oil-oil double emulsion. Scanning electron microscopy showed the nanoparticles to
be relatively spherical with a geometric mean diameter of 147 nm (with a geometric
standard deviation of 1.3) (Figure 1A). The release kinetics of MUC4β from 20:80 showed
a burst of ca. 20% at early time points followed by slow, sustained release with smaller
amount of protein released over 30 days. The data showed that after one month, the
hydrophobic 20:80 CPTEG:CPH particles released ca. 25% of the encapsulated protein in
a near-zero order release profile, which was consistent with previous work on protein
release kinetics from CPTEG:CPH polyanhydrides formulations [22, 23, 27-29]. Finally, the
encapsulation efficiency of the MUC4β was determined to be 32 ± 1% (Figure 1B).
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3.2 MUC4 Nanovaccine Enhances Surface Expression of MHC and CoStimulatory Molecules on DCs
While the functional role of MUC4 in pancreatic cancer pathobiology has been
studied extensively, the immunogenicity of MUC4 protein has not been assessed until now.
To examine the antigenicity of MUC4β protein (MUC4) and characterize the potential of
MUC4 nanovaccine in activating CD86+ CD11c+ DCs (Supplementary Figure 1), flow
cytometry was used to measure expression of cell surface markers such as major
histocompatibility complex molecule class II (MHC II) and class I (MHC I), co-stimulatory
molecule CD80, and C-type lectin CD205 (DEC-205: DC maturation marker). Recombinant
MUC4β protein alone or delivered with empty nanoparticles did not upregulate surface
expression of MHC I and II on DCs over controls. However, a significant 4-fold increase in
mean fluorescence intensity (MFI) of MHC I and II was observed on DCs cultured with
MUC4 nanovaccine in contrast to unstimulated DCs. Moreover, DCs cultured with MUC4
nanovaccine expressed high levels of MHC II (2-fold higher) than LPS-stimulated DCs
(Figure 2 A & B). Furthermore, MUC4 nanovaccine enhanced the DC surface expression
of the co-stimulatory molecule CD80 by 75% when compared to MUC4 only treated DCs,
but no significant difference was observed in CD40 expression (Figure 2 C & D). In
addition, DC surface expression of CD205 was 60%, 20% and 25% higher on MUC4nanovaccine stimulated DCs when compared to unstimulated, LPS- and MUC4β proteintreated DCs (Figure 2E) suggesting a higher proliferation and maturation of DCs which is
shown in Figure 2F. Altogether, these results demonstrate that the MUC4 nanovaccine
significantly enhanced the expression of surface markers and co-stimulatory molecules
involved in DC maturation and antigen presentation.
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3.3 MUC4 Nanovaccine Induces Pro-Inflammatory DC Cytokine Secretion
Dendritic cells direct immune responses by not only cross-presenting antigens to
effector T and B cells, but also by secreting an array of cytokines to modulate these
responses. After culturing DCs with various treatment groups for 48 h, we observed that
the MUC4 nanovaccine significantly enhanced DC secretion of the cytokines IL-12p40, IL6, and IFNγ in comparison to untreated DCs and free MUC4 simulated DCs (Figure 3).
The amounts of IL-12p40 and IL-6 in culture supernatants of DCs treated with MUC4
nanovaccine were 40% and 30% higher than that of DCs stimulated with LPS respectively
(Fig 3A & B), and the levels of IFNγ were comparable between these two stimulants (Fig
3C). DCs treated with MUC4β alone (MUC4) or MUC4β mixed with empty nanoparticles
(MUC4+NP) expressed low or undetectable levels of cytokines, which were no different
from unstimulated DCs. Similar to the data obtained for surface expression of MHC II and
DC co-stimulatory molecules, encapsulation of MUC4β protein in 20:80 CPTEG:CPH
nanoparticles significantly enhanced DC cytokine production.

3.4 Single Immunization with MUC4 Nanovaccine Elicit Robust Anti-MUC4
Humoral Responses
Polyanhydride nanovaccines have been shown to generate germinal centers and B
cells thus leading to sustained serum antibody responses in a single dose [30]. Apart from
measuring antigen-specific antibody levels (which indicates the degree of humoral
stimulation), isotyping of antibodies (IgG1 and IgG2b levels) demonstrate the type of
immune responses (Th1 or Th2) generated through the determination of IgG2b:IgG1 ratios.
The presence of high levels of antigen-specific IgG2b antibodies over IgG1 antibodies
indicates preferred isotype-switching to Th1 type responses, whereas low IgG2b:IgG1 ratio
is indicative of a Th2 type response [31]. To investigate if a single immunization with MUC4
nanovaccine induced robust humoral immune responses, animals were immunized
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subcutaneously with MUC4β-loaded 20:80 CPTEG:CPH nanoparticles. Serum antibodies
were detected at 1:1000 serum dilution in mice that were immunized with MUC4β alone,
MUC4β mixed with empty nanoparticles and MUC4 nanovaccine. Antibodies against
MUC4β were detected at higher dilutions in mice administered MUC4β only and MUC4
nanovaccine, but not when free protein was mixed with empty particles (Figure 4A).
Since it has been shown that MUC4 peptides induce primarily IgG1 Th2 antibodies and not
IgG2b [19], we evaluated the isotypes of the antibodies in MUC4β-immunized mice. Mice
immunized with the MUC4 nanovaccine demonstrated a high IgG2b:IgG1 ratio, whereas
mice immunized with MUC4β alone had a low IgG2b:IgG1 antibody ratio (Figure 4B).
These results indicate that encapsulation of MUC4β protein into 20:80 CPTEG:CPH
nanoparticles modulates the immune response towards a Th1 phenotype , which could
likely provide anti-tumor protection.

3.5 Immunization with MUC4 Nanovaccine Enhances the Presence of
Inflammatory Cytokines in Sera
Since the analysis of antibody isotypes demonstrated an induction of a Th1 immune
response, we also investigated the presence of Th1 cytokines (IL-12p40, IL-6, IL1β, and
IFNγ) in sera of immunized mice. Sera from MUC4 nanovaccine immunized mice had a
slightly higher increased mean amount of IL-6 compared to MUC4 and MUC4+NP
immunized mice (Figure 5A). In addition, sera from MUC4 nanovaccine immunized mice
had significant amounts (~50 fold increase) of IL1β Th1 cytokine when compared to other
treatment groups and PBS-treated mice (negative control) (Figure 5B) that correlates with
Th1 isotype switching of antibodies in these mice. The amounts of IL-12p40 and IFNγ were
below detection levels in all treatment groups (data not shown).
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4. Discussion
To date vaccine studies involving mucins have been based on selected peptides
which have limited repertoire of immunogenic epitopes. In pre-clinical studies, these
vaccines have not shown promising results which could be attributed to studies done only
with the tandem repeat regions of mucins including MUC4. Recombinant proteins could
address these limitations by presenting the entire spectrum of possible epitopes present
on the original antigens in an unbiased manner [3]. In this study, the β-subunit of MUC4
was expressed in a bacterial system and its immunogenicity was investigated. The data
presented showed that MUC4β (MUC4) induces a Th2 type immune responses such as
low expression of MHC-I and II complexes and co-stimulatory molecule CD80 (Fig 2 A-C),
and low levels of inflammatory cytokine generation by pulsed DCs (Fig 3 A-C). In addition,
mice immunized with only MUC4 produced significantly high levels of Th2 IgG1 antibodies
to MUC4 (Fig 4B). This indicated that utilizing the free protein by itself will likely not provide
an effective immunotherapeutic response. Th2 immune responses have been well
established to promote tumor pathogenesis and aggressiveness, whereas shifting the
immune response to Th1 phenotype provides anti-tumor protection [32-34]. Thus, we
encapsulated MUC4β into 20:80 CPTEG:CPH nanoparticles (MUC4 nanovaccine) and
investigated whether the MUC4 nanovaccine could enhance activation of dendritic cells
and modulate Th1 type humoral responses in vivo.
The MUC4 nanovaccine enhanced surface expression of MHC I and MHC II in
CD86+ CD11c+ DCs (Figure 3 A-B), which are implicated in presentation of antigen to T
cells and B cells, along with CD80 (Figure 3C), a co-stimulatory molecule required for
activation of naïve CD4 helper T cells. Proper antigen presentation followed by secondary
activation signal provided by CD80 is crucial in programming effector immune cells to
specifically target the cancer cells. Upregulation of these markers by MUC4-nanovaccine,
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when compared to the free MUC4 pulsed DCs, suggests that the encapsulated
formulation was able to reprogram the DCs from Th2 to a Th1 response phenotype.
Further, we observed that only stimulation with MUC4-nanovaccine enhanced DC
secretion of the cytokines IL-12p40, IL-6 and IFNγ in vitro when compared to free MUC4
or free protein mixed with empty nanoparticle (MUC4+NP) that corroborated with the DC
activation marker expression data. These results indicate that the encapsulation of
MUC4β protein in CPTEG:CPH nanoparticles is crucial to enhancing the immunogenicity
of recombinant MUC4β. Thus, the result suggests that the encapsulation of MUC4β
protein in CPTEG:CPH polymers is important for modulating the immunogenic response
of Th2-inducing recombinant MUC4β.
Previously, it has been shown that a single immunization of polyanhydride
nanovaccines can induce high antibody titers and provide protective immunity against
multiple pathogens in mice [28, 35]. Additionally, it is important to consider the quality of
antibody response generated by the nanovaccine, which may be characterized by the
specificity, avidity and isotype profile of the antibody response [36]. It is therefore
noteworthy that MUC4-nanovaccine immunized mice had the highest IgG2b:IgG1 ratio
which indicates Th1 type antibodies, whereas MUC4β alone or in combination with blank
nanoparticles preferentially induced Th2 type IgG1 anti-MUC4β antibodies in alignment
with its immunogenic nature (Figure 4B). This observation supports our in vitro
observation that encapsulation of MUC4β into polyanhydride nanoparticles likely plays a
crucial role in activating dendritic cells in favor of Th1 type immune responses, which was
further validated with the detection of higher levels of IL-6 and IL-1β cytokines (Figure 5).
The data herein shows encapsulating MUC4β in 20:80 CPTEG:CPH nanoparticles is an
effective strategy to activate dendritic cells in MUC4-specific manner and modulate the
response towards an anti-tumor Th1 phenotype. The presence of IgG2b antibodies could
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possibly further provide immunity against MUC4-expressing tumors by inducing antibodydependent cellular cytotoxicity (ADCC) or antigen-mediated tumor killing by NK cells that
can recognize the FcR region of antibodies bound to tumor cells [37, 38]. The current
studies provide a basis for investigating the use of the MUC4 nanovaccine as an
immunotherapeutic strategy in cancer models that overexpress MUC4 as a tumorassociated antigen.

5. Conclusion
Our data have clearly demonstrated that the MUC4-nanovaccine enhances DC
surface expression of both MHC molecules and co-stimulatory ligands, and Th1 cytokine
secretion. Further, in in vivo studies, the MUC4 nanovaccine effectively induced
production of anti-MUC4β antibodies and isotype-switching of these antibodies to primarily
IgG2b (Th1 type) isotypes, which typically correlates to anti-tumor immune responses [39].
Thus, this work demonstrates that polyanhydride MUC4 nanovaccines are a promising
platform for immunotherapies against pancreatic cancer.
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Figure 1: Synthesis, encapsulation and release kinetics of MUC4
nanovaccine.
Endotoxin-free recombinant MUC4β protein was isolated from Rosetta bacteria
and purified by affinity chromatography. 20:80 CPTEG:CPH nanoparticles encapsulating
3% MUC4 were synthesized via a solid/oil/oil double emulsion flash nanoprecipitation
process. SEM images of 20:80 CPTEG :CPH nanoparticle encapsulated recombinant
mucin fragment: MUC4-β (A). Antigen release kinetics were characterized by incubating
the nanoparticles in PBS and measuring MUC4 released at regular intervals with a
microBCA assay. 3% MUC4-loaded 20:80 CPTEG:CPH nanoparticles exhibited an initial
burst (20%) release of protein followed by sustained release. The encapsulation efficiency
of protein was determined to be 32%, suggesting low affinity between the polymer and
MUC4 protein.
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Figure 2: MUC4 nanovaccine activates DCs and induces expression of MHC
II and co-stimulatory molecules.
Flow cytometry analysis demonstrated that MUC4 nanovaccine have activated
DCs robustly like the LPS positive control. MUC4β (MUC4) protein has Th2 immunogenic
activity that abrogates DC activation and expression of MHC and co-stimulatory
molecules. Free MUC4 mixed with empty nanoparticles (MUC4+NP) slightly increases the
immunogenicity of MUC4β, but only MUC4 nanovaccine could significantly activate DCs,
suggesting encapsulation of MUC4β is crucial for inducing a Th1 immune responses (AE). Increased DC proliferation was observed in MUC4 nanovaccine group compared to
unstimulated DCs and other MUC4 treatment groups (F). Statistical significance was set
at p<0.05. ANOVA analysis of the data was p<0.05. Statistical comparison between
MUC4, MUC4+NP & US with MUC4 nanovaccine is denoted by #, * & + respectively.
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Figure 3: MUC4 nanovaccine induced robust Th1 DC cytokine secretion.
Cytokine analysis demonstrated that MUC4 nanovaccine activated DCs secrete
Th1 cytokines. Free MUC4 mixed with empty nanoparticles (MUC4+NP) and MUC4
pulsed DCs have low expression of Th1 cytokines, suggesting that mixing of a strong
adjuvant was not able to modulate the immune response induced by MUC4. Only
encapsulation of MUC4 could modulate and reprogram DCs to secrete IL12, IL6 and IFNγ
Th1 cytokines (A-C). Statistical significance was set at p<0.05. ANOVA analysis of the
data was p<0.05. Statistical comparison between MUC4, MUC4+NP & US with MUC4
nanovaccine is denoted by #, * & + respectively.
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Figure 4: Mice immunized with MUC4β nanovaccine generated anti-MUC4β
Th1 humoral response.
Eight week-old C57BL/6 mice were immunized with a single dose and serum was
collected for detecting antibodies. ELISA studies showed that MUC4, MUC4+NP and
MUC4 nanovaccine immunized mice serum carried MUC4β antibodies (A). Further,
isotyping of MUC4β antibodies demonstrated that isotype switching was predominantly to
Th1 IgG2b in MUC4 nanovaccine immunized mice, whereas in MUC4 immunized mice it
was predominantly in IgG1 Th2 isotype (B). Statistical significance was set at p<0.05.
ANOVA analysis of the data was p<0.05. Statistical comparison between MUC4,
MUC4+NP and US with MUC4 nanovaccine is denoted by #, * & + respectively.
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Figure 4

158

Figure 5: Presence of Th1 cytokines in mice immunized with MUC4β
nanovaccine.
MUC4 nanovaccine immunized mice serum had significantly higher levels of IL6 (A) and
IL1β (B) Th1 cytokines that correlated with the predominant Th1 IgG2b MUC4β antibodies
present in these mice. Statistical significance was set at p<0.05. ANOVA analysis of the
data was p<0.05. Statistical comparison between MUC4, and MUC4+NP with MUC4
nanovaccine is denoted by # & * respectively.
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Supplementary Figure 1: MUC4 nanovaccine elicits robust proliferation of
dendritic cells (DCs).
Total of 1X105 DCs were pulsed with free MUC4β protein (MUC4), free MUC4β
protein mixed with empty nanoparticles (MUC4+NP) and MUC4-nanovaccine.
Unstimulated DCs (US) and LPS-treated DCs serve as negative and positive controls.
Antigen-matured DCs were characterized as CD86hi CD11c positive (CD86+CD11c+) cells.
MUC4 nanovaccine strongly stimulates DCs and robust 3-fold proliferation is observed
when compared to MUC4-pulsed DCs.
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CHAPTER 5: COMBINING IMMUNE
CHECKPOINT BLOCKADE WITH
MUC4 NANOVACCINE FOR PC
TREATMENT
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1. Synopsis
Pancreatic cancer (PC) is a highly metastatic and therapy-resistant malignancy
characterized

by

immunosuppressive

tumor

microenvironment

(TME)

mucin

overexpression. Immunotherapy strategies for PC treatment are constantly being
developed and tested in clinical trials but have achieved underwhelming outcomes. MUC4
is the most differentially overexpressed mucin and functionally contributes to PC disease
aggressiveness. Our previous studies have demonstrated that MUC4 is immunogenic in
PC patients and is thus an ideal candidate for targeted therapies. We developed a novel
vaccine using recombinant MUC4 fragments and exploiting adjuvant-like properties of an
amphiphilic polyanhydride-based nanoparticle delivery system. In addition, we showed
that recombinant human MUC4β protein encapsulated in amphiphilic polyanhydride
nanoparticles (MUC4 nanovaccine) successfully activates dendritic cells and induces Th1
anti-MUC4β antibodies in immunized C57BL/6 mice. Tumor cells are also known to
express programmed death ligand 1 (PD-L1) to suppress effector immune cells activity
via the PD-L1-PD-1 axis. Our preliminary study elucidated that MUC4 nanovaccineimmunized mice exhibited slower tumor growth kinetics than unimmunized control mice.
However, we did not observe complete tumor regression and detected PD-L1 expression
on MUC4-expressing tumors only. Based on this, we rationalized that PD-L1 expression
by MUC4-expressing tumor cells suppressed and inhibited the therapeutic benefits of the
nanovaccine in-vivo. The strong involvement of MUC4 in disease aggressiveness and PDL1 in immunosuppression thus makes a compelling case for their combined targeting.
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2. Background and Rationale
The PC tumor microenvironment is a complex relationship between cellular
components, desmoplasia and cytokine milieu. PC’s dense stroma/desmoplasia harbor
immune cells such as TAMs, MDSCs, and Treg cells that directly inhibit the activity of
effector CD4+ and CD8+ T-cells. These pro-tumor immune cells further secrete antiinflammatory Th2 cytokines like IL-4, IL-10 and IL-13, which negatively regulate the
infiltration and functionality of effector immune cells by precluding immunological
recognition [1-3]. To overcome the immune suppression elicited by the TME of pancreatic
cancer, reprogramming of patient’s immune system and generation of strong anti-tumor
Th1 responses are necessary. Therapeutic cancer vaccines have emerged as a tool to
reprogram and activate the patient’s immune system in a tumor antigen-specific manner
to effectively target tumor cells [4, 5]. Cancer vaccines have seen limited clinical success
in some solid tumors such as lung cancer, breast cancer and renal cancer. A major factor
that could improve the efficacy of these vaccines is firstly identifying TAAs that could be
targeted [5]. Our previous study has identified MUC4 to be immunogenic in PC patients,
suggesting that these patients have compromised peripheral tolerance.
A second major factor is a generation of robust anti-tumor responses to cancer
vaccines to overcome peripheral immune tolerance and escape immune suppression of
TME. To break tolerance and constrain immune suppression, selection of a strong
immunological adjuvant to be combined with the antigen is required [5-7]. Adjuvants are
an instrumental component of a potent vaccine that enhances the immunogenicity of the
antigen and increases the antigen-specific immune response. However, developing a
cancer vaccine with a successful adjuvant is not easy because the adjuvant must preserve
the antigen and needs to be safe, potent and economically viable [6, 7]. We developed a
novel MUC4 nanovaccine by encapsulating human MUC4β recombinant protein in
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pathogen-mimicking amphiphilic polyanhydride nanoparticles. We observed that the
MUC4 nanovaccine elicited robust activation of DCs by upregulating surface expression
of DC activation markers, as well as secretion of Th1 cytokines like IL12, IL6 and IFNγ.
Further, we elucidated that mice immunized with MUC4 nanovaccine carried high levels
of Th1 IgG2b anti-MUC4β antibodies circulating in their serum. These data provide initial
evidence that MUC4 nanovaccine could potentially serve as a potent immunotherapy
strategy to treat PC.
The PD-L1 co-inhibitory molecule expressed on tumor cells binds to its receptor
programmed cell death protein 1 (PD-1) present on T cells and negatively regulates T-cell
signaling and effector functions [8]. PD-1 is expressed only on antigen-experienced CD4+
and CD8+ T cells, as well as B cells, and is absent on resting T and B cells [9]. Its ligand
PD-L1, also known as cluster of differentiation 274 (CD274) or B7 homolog 1 (B7-H1), is
expressed on activated DCs and macrophages[10], as well as non-lymphoid tissues like
cancer cells upon IFNγ stimulation [11]. PD-L1 is also expressed in peripheral tissues,
thus suggesting its role in peripheral tolerance against self-reactive T and B cells, and may
serve in regulating inflammatory responses at these sites [12]. PD-L1, upon binding to its
receptor PD-1, inhibits T cell proliferation and its effector functions by inducing apoptosis.
In addition, this axis promotes differentiation of CD4+ T cells into Foxp3+ regulatory T cells
[13-15].
One of the major challenges that have emerged from recent preclinical studies is
the counter PD-L1 mediated-suppression elicited on infiltrating effector lymphocytes by
tumor cells, therefore inhibiting the efficacy of these vaccines [16-18]. Expression of PDL1 by tumor cells is an indicator of an active immune interaction occurring between
cytotoxic CD8+ T-cells and tumor cells. Blockade of PD-1 receptor on effector T-cells to its
ligand PD-L1 by PD-1 inhibitors have shown some promise in rescuing anti-tumor effects
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as been discussed in the following review [1]. However, PC patients show differential
expression of PD-L1 in tumors due to the various degree of effector T-cells infiltration
found in the TME [19]. Combined high percentage of infiltrating CD8+ T-cells and high PDL1 expression is correlated with lymph node metastasis and poor survival of PC patients
[20-22].
Based on the data, our working goal was to investigate whether MUC4
nanovaccine could provide immunity against MUC4 tumor-bearing mice. Our preliminary
data suggest that MUC4 nanovaccine has the potential to induce anti-tumor responses.
We observed a positive correlation between TILs and tumor regression. Accumulation of
infiltrating CD8+ and CD4+ T cells was greater in mice receiving the MUC4 nanovaccine
compared to soluble MUC4 delivered with blank nanoparticles (MUC4+NP), indicating the
benefit of sustained availability of antigen via encapsulation. However, we didn’t achieve
complete clearing of the MUC4-expressing tumor and thus investigated the PD-L1
expression in them. We did observe that MUC4 tumors had high expression of PD-L1 on
tumor cells whereas only low expression of PD-L1 was seen in vector control tumors.
These results suggest that MUC4 nanovaccine combined with checkpoint blockade could
have enhanced therapeutic potential.

3.

Results

3.1 The Cytotoxic Killing of MUC4-Expressing Cell Lines by CTLs
miniMUC4 construct captures the entire structure of original human MUC4 protein
but has approximately 90% of the VNTR region missing due to which it runs at a lower
molecular weight of 250-300 kDa in 2% agarose SDS gel [23]. Our cytotoxicity assay
demonstrated that T-cells activated ex vivo by MUC4 nanovaccine-pulsed DCs mediated
25% higher antigenic-specific killing of miniMUC4 expressing-KPC960 cells when
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compared to T-cells activated by MUC4+NP-pulsed DCs (Figure 1). Based on this, we
proposed to elucidate the therapeutic potential of MUC4 nanovaccine in in vivo model.

3.2 MUC4 Nanovaccine Immunized Mice have Slower Tumor Growth Kinetics
To fully understand the preventive and therapeutic role of MUC4 nanovaccine, we
pre-immunized the mice with primary dose and first booster. After tumor cells implantation,
once the tumor volume reached 100 mm3, we immunized the mice with a lower second
booster dose (Figure 2A). We observed that miniMUC4 tumors had slower growth kinetics
with respect to its contralateral vector control KPC960 tumors. In addition, miniMUC4
tumors in MUC4 nanovaccine-immunized mice had overall lower tumor volume when
compared to the unimmunized control mice (Figure 2B & C).

3.3 MUC4 Nanovaccine Enhanced Immune Cell Infiltration in miniMUC4
Tumors
Our observation of slower tumor growth kinetics and overall smaller tumor volume
of miniMUC4 tumors, when compared to vector control tumors, in MUC4 nanovaccineimmunized mice, made us curious to investigate the immune cell infiltration in miniMUC4
tumors. Hematoxylin and eosin staining of tumor tissue sections showed a MUC4-specific
immune cell infiltration in miniMUC4 tumor cells in the MUC4 nanovaccine immunized
mice (Figure 3A). We did observe some antigen-specific immune cell infiltration in
miniMUC4 tumors of free soluble MUC4-immunized mice, but the percentage of infiltration
was significantly lower than MUC4 nanovaccine-immunized mice. The pathologist noticed
an area of necrosis proximal to the immune infiltrate region, which were quantified. We
found a positive correlation between tumor necrosis and the degree of immune cell
infiltration in miniMUC4 tumors. MUC4 nanovaccine-immunized mice had 5% higher
tumor necrosis than other groups where the MUC4 antigen was provided (Figure 3B).
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Further, we investigated the percentage of CD8+ and CD4+ T-cells infiltrated in miniMUC4
tumor cells by immunofluorescence and confocal microscopy (Figure 4 A-B). We
observed that in MUC4 nanovaccine-immunized mice, 65% CD8+ and 25% CD4+ of
infiltrating T-cells were present in miniMUC4 tumors, whereas only 33% CD8+ and 9%
CD4+ of infiltrating T-cells were detected in miniMUC4 tumors of MUC4+NP-immunized
mice (Figure 4 C-D). These data provide a rationale for the slower miniMUC4 tumor
growth kinetics observed in MUC4 nanovaccine-immunized mice.

3.4 MUC4 Nanovaccine Induces IFNγ Mediated PD-L1 Expression on
miniMUC4 Tumor Cells
Our data suggest that MUC4 nanovaccine is inducing immunological targeting of
miniMUC4 tumors; however we did not achieve complete tumor regression. To overcome
immunosuppression of PC tumor cells, it is well understood that cancer vaccines need to
generate robust cellular responses as well as high levels of Th1 cytokines. To evaluate
whether MUC4 nanovaccine was able to induce strong cytokine secretion, we analyzed
through flow cytometry the levels of Th1 cytokines produced by effector T cells. Our
analysis demonstrated that significantly high levels (P<0.01) of Th1 CD4+ (Tbet-positive)
T-cells were present in MUC4 nanovaccine-immunized mice. In addition, both CD8+ and
CD4+ T-cells produced robust levels of IFNγ cytokine in contrast to unimmunized mice
(Figure 5 A-B).
Survey of literature has elucidated that IFNγ secreted by effector T-cells could
potentially induce PD-L1 expression by tumor cell as a counterattack mechanism and
inactivate the functionality of cytotoxic T-cells [11]. Since our data showed that significantly
higher levels of IFNγ are produced by effector T-cells, we were curious to understand
whether IFNγ was inducing PD-L1 expression on miniMUC4 tumor cells that lead to the
limited success of MUC4 nanovaccine in our in vivo mouse model. IHC staining of PD-L1
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revealed that PD-L1 was expressed on the surface of miniMUC4 tumor cells and stroma
from MUC4 nanovaccine-immunized mice (Figure 5C). There was some low-intensity
stromal staining and no tumor cell staining was observed in vector control tumors, whereas
cellular surface staining of PD-L1 was observed on miniMUC4 tumor cells, suggesting an
active cross-talk between effector T-cells and tumor cells, which corroborates with the high
degree of immune infiltration detected in miniMUC4 tumors removed from MUC4
nanovaccine-immunized mice.

4. Discussion
The present study investigated whether MUC4 nanovaccine could elicit anti-tumor
responses and abrogate from tumor growth. Studies from our lab have shown that MUC4
nanovaccine could potentially activate dendritic cells and humoral responses. But whether
the cancer vaccine could provide cellular immunity against MUC4 expressing tumor cells
needed to be investigated. Thus, we did a preliminary study to investigate the preventive
and therapeutic potential of MUC4 nanovaccine in a subcutaneous PC tumor mice model.
Our ex vivo experiments provided evidence that MUC4 nanovaccine could activate
effector T-cells in MUC4-specific manner and induce robust cytotoxic killing of MUC4
expressing KPC960 cells. Based on this data, we investigated whether MUC4
nanovaccine could inhibit the growth of MUC4 expressing tumors and lead to complete
tumor regression. Our results suggest that even though MUC4 nanovaccine could
significantly reduce the tumor growth kinetics and tumor volume along with increased
immune cells infiltration and Th1 cytokine production, complete tumor regression was not
attained in these immunized mice.
One of the reasons for not being able to attain a complete regression was that this
study was done in C57BL/6-FBP mixed background mice, due to which different HLA
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haplotypes could lead to limited activation of cytotoxic T cells and recognition of tumor
cells by CTLs. Another reason for the limited success was due to the immune suppression
exhibited by the PD-L1 expressed by tumor cells on CTLs. We propose that IFNγ secreted
by effector T-cells induced PD-L1 immunoinhibitory ligand expression on miniMUC4 tumor
cell surface as an immunosuppressive response and thus induced inactivation of CTLs
that resulted in reduced tumor volume but no complete regression.
To evaluate and elucidate the full potential of MUC4 nanovaccine as a potent
immunotherapy strategy for PC, we need to study MUC4 nanovaccine in a syngeneic PC
mice model. Further to fully replicate clinical settings, we are required to study the
nanovaccine in human MUC4 transgenic genetically engineered PC mice model. Our data
suggest that combining checkpoint blockade therapy with MUC4 nanovaccine could
potentially levitate the immunosuppression exhibited by PC tumor, which needs to be
investigated in the future.
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Figure 1: MUC4 nanovaccine pulsed DCs activated CTLs in an antigen-specific
manner and induced cytotoxic killing of miniMUC4-expressing murine pancreatic
cancer cell lines.
Spontaneous pancreatic cancer mouse model (KPC)-derived pancreatic cell line
(KCT-960) was transfected with the Mini-MUC4 construct and was used for LDH
cytotoxicity assay. The assay showed the specific killing of Mini-MUC4 expressing cells
compared to vector control (A).
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Figure 1
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Figure 2: Schematic representation of tumor implantation and treatment by MUC4
nanovaccine. MUC4 nanovaccine-immunized mice showed a decrease in tumor
growth.
Immunization of mice was done as indicated. Mice were injected with 1x106 cells
of miniMUC4 or Vector expressing into right and left flanks of mixed background mice
(n=5), respectively. Immunization of tumor-bearing mice to analyze the efficacy of the
MUC4 nanovaccine (A). Tumors were harvested at day 23. MUC4 nanovaccine-treated
mice (inverted green triangle) showed tumor size reduction (below the red median line) in
mini-MUC4 tumors with respect to contralateral vector control tumor, in comparison to
unimmunized control mice (orange sphere) (B). Representative photograph of tumors
isolated from Control and MUC4 nanovaccine immunized mice group (C).
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Figure 3: MUC4 nanovaccine enhanced immune infiltration and corresponding
necrosis in the miniMUC4 tumor.
The miniMUC4- or vector-expressing KCT-960 cells were implanted into
contralateral right and left flank of the same mouse, respectively. These mice were preimmunized and received second booster post-tumor implantation, with MUC4 free protein
mixed with empty CPTEG: CPH 20:80 nanoparticles (MUC4+NP) in PBS, MUC4 free
protein in PBS and MUC4 nanovaccine in PBS as indicated in Figure 2A. Mice immunized
with the MUC4 nanovaccine formulation demonstrated increased infiltration of immune
cells (A). Pathological analysis of tumor tissues showed that encapsulated MUC4 induced
greater necrosis in MUC4-expressing tumors compared to all other treatment groups (B).
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Figure 4: CD4+ and CD8+ T cell populations in miniMUC4 or Vector expressing
mouse pancreatic ductal (PDAC) tumors.
Mice were pre-immunized and received second booster post-tumor implantation,
with MUC4 free protein mixed with empty CPTEG: CPH 20:80 nanoparticles (MUC4+NP)
in PBS, MUC4 free protein in PBS and MUC4 nanovaccine in PBS as indicated in Figure
2A.Tumor tissues were stained with CD8 (A and B) CD4 (C and D) T cells surface marker
antibodies and were subjected to Immunofluorescence (IF) analysis by EVOS microscope.
Quantification of infiltrating CD8+ and CD4+T cells in miniMUC4 or Vector expressing
PDAC tumors in MUC4 nanovaccine- or miniMUC4+NP-immunized mice (p<0.01 by
Tukey’s t-Test) (B and D).
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Figure 5: MUC4 nanovaccine immunized mice activates T-cells in Th1 phenotype
that induces the corresponding expression of PD-L1 by miniMUC4 tumor cells.
Mice pre-immunized with MUC4 nanovaccine showed that MUC4-delivered
through nanoparticles induced Th1 immune responses of both CD4+ and CD8+ T-cells in
immunized mice compared to unimmunized control (** signifies p<0.01 by Tumey’s t-Test)
(A & B). IHC analysis for PD-L1 on MiniMUC4 tumors and vector control tumors treated
with MUC4 nanovaccine showed an upregulation in PD-L1 expression only in MiniMUC4
tumors, indicating an immunosuppressive response by MiniMUC4 tumors (C).
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CHAPTER 6: SUMMARY,
CONCLUSIONS AND FUTURE
DIRECTIONS
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1. Summary and Conclusion
PC has an elaborate immunosuppressive microenvironment and immunotherapy
has emerged as a tool to effectively target PC and its microenvironment [1]. Developing
immunotherapy strategies for PC treatment comes with its own challenges that are: i)
identifying a tumor-associated antigen that could be targeted, ii) identifying biodegradable
adjuvants that could efficiently deliver antigens while preserving their antigenicity, iii)
eliciting robust anti-tumor responses on the face of immunosuppression and iv)
overcoming peripheral tolerance and immunosuppression elicited by the tumor.
Mucins are overexpressed in PC tumor cells and, due to their overexpression and
aberrant glycosylation, they have emerged as potential candidates for targeted
immunotherapeutic strategies for PC treatment [2]. MUC1 is one of the well-studied
candidates for PC immunotherapy strategies but have attained only limited success in
clinical trials. Most of these immunotherapies are MUC1 peptide-based vaccines that
capture limited epitopes and excludes possible antigen epitopes present on the entirety of
the protein. In addition, MUC1 is expressed at low levels in all normal tissues thus it
doesn’t provide tumor specificity [1-3]. Over the past several years, various aspects of
MUC4 function and regulation in PC has been investigated [4-6]. In contrast to MUC1,
MUC4 has restricted expression on normal tissues and is undetectable in normal pancreas
[7, 8], whereas it is differentially overexpressed in PC tumor and its expression gradually
increases with the disease progression [4, 8], thus MUC4 overexpression provides a
spatiotemporal specificity to PC tumors that could be immunogenic. Further, MUC4 has
been extensively studied and reported to be instrumental in PC pathogenesis [4], therefore
we proposed that MUC4 could serve as a potential target for PC immunotherapy.
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1.1 Pancreatic cancer patients have compromised peripheral tolerance
against MUC4.
Here we focused on understanding whether the tolerance against MUC4 in PC
patients is compromised. Peripheral tolerance is comprised of CD4 T helper cells and Bcells and identification of tumor-associated antigens activate B-cells to generate
autoantibodies against those antigens. Thus detection of autoantibodies against MUC4 in
PC patients will be an indicator of compromised peripheral tolerance in those patients.
Our data demonstrated that autoantibodies are present against the recombinant MUC4β
protein as well as to randomly selected MUC4 peptides derived from the entirety of MUC4
protein. Further our analysis showed that the autoantibodies to MUC4 peptides are
generated in a PC-specific manner and negligible in healthy or chronic pancreatitis
individuals. Additionally, IgM autoantibodies to MUC4 peptides (A2, D3 and B1)
significantly correlated with PC patient overall survival. Thus suggesting that
immunologically targeting MUC4 through a unique immunotherapy platform could exploit
this compromised tolerance and generate efficacious anti-tumor responses potentially
contributing to clinical success.

1.2 Encapsulation of MUC4β protein in novel amphiphilic polyanhydrides
nanoparticles shifts its immunogenicity from Th2 to Th1 phenotype, and
induces robust DC activation and humoral responses.
Most of the cancer vaccines developed are peptide-based due to the difficulty of
encapsulating proteins while preserving their antigenicity and allowing sustained release
in the circulation for activation of immune cells [9, 10]. Prior to our study, isolation and
purification of MUC4 recombinant proteins and its characterization have not been
achieved. Here we successfully purified the MUC4β protein from bacterial expression
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system, and encapsulated the protein in novel amphiphilic polyanhydrides nanoparticles
to develop MUC4 nanovaccine. Polyanhydride nanoparticles is a suitable platform due to
its pH-neutral core that stabilizes protein, pathogen-mimicking properties and tunable
release kinetics that enable immune-modulation [11-16]. In addition, MUC4 recombinant
protein provides a wide repertoire of potential epitopes when compared to single epitope
peptide-based immunotherapy strategies thus potentially eliciting a robust and sustained
anti-tumor Th1 immune responses.
We demonstrated that soluble MUC4βprotein alone activates DCs in the Th2
pathway. It is well understood that Th1 immune responses have anti-tumor outcomes,
therefore the protein by itself is not suitable for PC treatment. However, encapsulation of
MUC4β protein shifted the overall response to Th1 phenotype. MUC4 nanovaccine
robustly activated DCs and induced both surface expression of activation markers and
secretion of Th1 cytokines. Further, in the immunized mice MUC4 nanovaccine induced
generation of Th1 IgG2b humoral responses, which was not observed in mice immunized
with soluble MUC4 or MUC4+NP groups. Thus indicating that the encapsulation of MUC4β
in the nanoparticles is crucial for reprogramming the immune responses from Th2
phenotype to Th1 phenotype.

1.3 MUC4 nanovaccine induces immune infiltration in miniMUC4 tumors in
an antigen-specific pathway.
Cancer vaccines have been shown to induce effector immune cell infiltration in
tumors in an antigen-specific pathway that affects the overall tumor growth [17]. Here we
tried to elucidate the therapeutic potential of a MUC4 nanovaccine in eliciting robust antitumor responses in a PC subcutaneous tumor mouse model. Our study showed that
miniMUC4 tumors in mice immunized with MUC4 nanovaccine had slower tumor growth
and lower tumor volume with respect to vector control tumors on the contralateral flank of
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the same mice. These data suggested a MUC4-specific immune response in these
vaccinated mice. Upon further evaluation, we observed that only in MUC4 nanovaccine
immunized mice there is enhanced total immune cell infiltration and also effector T cell
infiltration which correlated with high levels of necrosis seen in miniMUC4 tumors. Despite
high T-cell infiltration, we were unable to attain complete regression in miniMUC4 tumors.
Due to the high levels of IFNγ generated by T-cells isolated from MUC4 nanovaccineimmunized mice, we hypothesized that tumor cells are expressing PD-L1 upon IFNγ
induction on the cell surface and inhibiting effector T-cells, cytotoxic activity. Our IHC
analysis validated our hypothesis and we observed PD-L1 surface expression on
miniMUC4 tumor cells. Thus, in conclusion, MUC4 nanovaccine could potentially be
exploited as a PC treatment strategy.

2. Future Directions
While our studies elucidated the potential of MUC4 nanovaccine as a potent
strategy for treating pancreatic cancer, the fact that our in vivo tumor model study was
done in mixed background mice limits the clinical translation of our work. To fully
understand the anti-tumor potential of MUC4 nanovaccine we are required to perform our
studies in a syngeneic mice model. Our lab has recently developed murine PC cell lines
derived from the C57BL/6 pure background KPC mice model. We will be transfecting
these cells with miniMUC4 plasmid construct and test the cytotoxic killing of this human
MUC4-expressing syngeneic mouse PC cell lines by MUC4 nanovaccine-activated Tcells. This study will give us a better understanding of the potential of MUC4 nanovaccine
activating T-cells in a MUC4 antigen-specific manner.
Even though our in vitro and subcutaneous study with human MUC4 expressing
syngeneic mice model will elucidate the therapeutic potential of MUC4 nanovaccine, the
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model does not recapitulate PC patient’s immune system where immune cells might
recognize MUC4 on tumor cells as self-antigen and are tolerant towards MUC4. Our
autoantibodies study suggests that MUC4 is immunogenic in PC patients and based on
serum reactivity some PC patients might respond well to MUC4 based immunotherapies.
To recapitulate this clinical setting and validate our hypothesis, our lab (with the help of
Dr. Satyanarayana Rachagani) has recently developed a human MUC4 transgenic mice
model. We will utilize this model to primarily address two questions: i) whether MUC4
nanovaccine could break the immunological tolerance in MUC4 transgenic PC mice model
and effectively kill MUC4-expressing PC tumor cells, and ii) whether MUC4 nanovaccine
will lead to severe side-effects due to the non-specific recognition of MUC4 on other
normal tissues. Further we have also developed a human MUC4 transgenic KrasG12D Pdx1 Cre spontaneous PC mice model that expresses MUC4 only on pancreatic tumor cells.
This mice model will be used to study whether MUC4 nanovaccine could either stabilize
or regress human MUC4 expressing spontaneous PC tumor. A culmination of all these
studies will provide us with a clearer understanding of the efficacy of MUC4 nanovaccine
as a therapy strategy.
There is very limited knowledge about MUC4’s contribution to the PC
immunosuppressive TME. We are curious to investigate the correlation of MUC4
expression with the immune-phenotype of resected tumors, and cross-refer the
observation in our MUC4 transgenic KrasG12D Pdx-1 Cre spontaneous PC mice model
system. Further, PC tumors are fairly desmoplastic that restricts the infiltration of effector
T-cells. Our in vivo work provided evidence that PD-L1 is expressed on miniMUC4 tumor
cells as a counterattack to escape cytotoxic killing by cytotoxic CD8+ T cells. Thus, based
on the data that we will collect from MUC4 transgenic mice models, combining immunecheckpoint blockade agents such as anti PD-1 antibody and stroma cell depletion agents
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with MUC4 nanovaccine to enhance the therapeutic efficacy of the vaccine needs to be
tested.
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